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The quest for an efficacious HIV vaccine has resulted in several clinical trial failures, including the Step Trial,
which used a replication-incompetent adenovirus (AdV) vector called human adenovirus type 5 (HAdV-5).
Despite eliciting strong cellular immune responses, these trials were prematurely halted due to statistical
futility resulting from increased HIV acquisition in vaccinated individuals. The Step Study showed increased
HIV susceptibility in HAdV-5 baseline seropositive subjects, which complicates the use of HAdV-5 vectors
since pre-existing neutralizing antibodies (nAb) to HAdV-5 are prevalent worldwide. Sampling the unique
immunological phenotypes of the rectal mucosa - the site of HIV infection in the Step Study, and of AdV
persistence and trafficking - could help explain this trial, since only peripheral blood (PBMC) was collected
from subjects. We obtained rectal lamina propria T lymphocytes (rLPL) from a rhesus macaque (RM) model
vaccinated with a species-specific simian Ad type 7 (SAdV-7) or HAdV-5 vector. We hypothesized that AdV-
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T cells that are either already harbored in the gastrointestinal mucosa or traffic to this original site of infection.
The increased percentage of activated target cells upon SIV exposure would create a favorable environment for
increased SIV susceptibility. We show an increase in both AdV-specific and activated CD4+ memory T cells in
the rLPL after AdV vector vaccination relative to baseline, without significant changes in PBMCs. This led us
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demonstrated increased SIV infection in the vaccine group, this would show evidence of activation-induced
SIV susceptibility. Although we did not see an alteration in CD4+ memory T cell activation, we saw a trend
towards SIV acquisition in the SAdV-7 vector vaccinated group versus placebo. Future studies should be
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ABSTRACT 
CONSEQUENCES OF ADENOVIRUS VECTOR VACCINATION ON T CELL 
ACTIVATION AND SIV SUSCEPTIBILITY IN RHESUS MACAQUES 
Irene Bukh 
Michael R. Betts 
 The quest for an efficacious HIV vaccine has resulted in several clinical trial 
failures, including the Step Trial, which used a replication-incompetent adenovirus (AdV) 
vector called human adenovirus type 5 (HAdV-5). Despite eliciting strong cellular 
immune responses, these trials were prematurely halted due to statistical futility resulting 
from increased HIV acquisition in vaccinated individuals. The Step Study showed 
increased HIV susceptibility in HAdV-5 baseline seropositive subjects, which 
complicates the use of HAdV-5 vectors since pre-existing neutralizing antibodies (nAb) 
to HAdV-5 are prevalent worldwide. Sampling the unique immunological phenotypes of 
the rectal mucosa – the site of HIV infection in the Step Study, and of AdV persistence 
and trafficking – could help explain this trial, since only peripheral blood (PBMC) was 
collected from subjects. We obtained rectal lamina propria T lymphocytes (rLPL) from a 
rhesus macaque (RM) model vaccinated with a species-specific simian Ad type 7 
(SAdV-7) or HAdV-5 vector. We hypothesized that AdV-based vector vaccination in 
macaques previously exposed to AdV would activate AdV-specific CD4+ memory T cells 
that are either already harbored in the gastrointestinal mucosa or traffic to this original 
site of infection. The increased percentage of activated target cells upon SIV exposure 
would create a favorable environment for increased SIV susceptibility. We show an 
increase in both AdV-specific and activated CD4+ memory T cells in the rLPL after AdV 
vector vaccination relative to baseline, without significant changes in PBMCs. This led us 
to a proof-of-concept study where we collected PBMCs and rLPL from 10 SAdV-7 vector 
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vaccinated and 10 placebo vaccinated RMs at baseline and week 2 post-vaccination. 
We performed low-dose escalating intra-rectal challenges weekly with SIVmac251 until 
SIV acquisition or 16 weeks post-vaccination. If we demonstrated increased SIV 
infection in the vaccine group, this would show evidence of activation-induced SIV 
susceptibility. Although we did not see an alteration in CD4+ memory T cell activation, 
we saw a trend towards SIV acquisition in the SAdV-7 vector vaccinated group versus 
placebo. Future studies should be cautious with the use of AdV vectors for mucosally 
transmitted pathogens, even for rare AdV serotypes due to T cell cross-reactivity and 
CD4+ memory T cell activation-induced susceptibility within mucosal sites.  
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CHAPTER 1 
General Introduction 
 
Origins of HIV and Epidemiology 
 Two laboratories identified Human Immunodeficiency Virus (HIV), the etiologic 
agent that causes Acquired Immunodeficiency Syndrome (AIDS), in 1983 1,2. HIV 
remains a significant public health concern, despite research seeking a cure for over 30 
years. It is estimated that 34 million people are living with HIV globally, which includes 
approximately 2.5 million new infections and 1.7 million AIDS-related deaths yearly. 
Although there appears to be a slight decrease in the total number of new infections and 
deaths, and an increase in the life expectancy of HIV-infected individuals due to better 
therapeutics and access to anti-retroviral therapy (ART), there is still no cure. In 
particular, sub-Saharan Africa has been dramatically affected by this epidemic, where it 
is estimated that a fifth of the population may be HIV positive 34. The limited access to 
treatment or care in impoverished regions across the world is a major issue that must be 
tackled in conjunction with continued research towards HIV eradication. 
 HIV is acquired via the transfer of bodily fluids, including blood, vaginal fluid, 
semen, and breast milk. HIV-positive individuals are most infectious during the acute 
phase, when the viral load is highest in the transmitting individual, through unprotected 
sex, intravenous drugs using contaminated needles, perinatally, and during breast-
feeding 5-8. While the predominant route of transmission varies in different parts of the 
world, over half of the infections that occur in the U.S. are a result of men who have sex 
with men (MSM), and ~25% are due to heterosexual contact (2).  
 There are two strains of HIV in humans – HIV-1 and HIV-2 – both of which 
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originated from zoonotic transfers from Simian Immunodeficiency Viruses (SIV) (SIVcpz 
and SIVsmm, respectively) in African non-human primates (NHP) 9,10. Molecular clock 
estimates indicate that HIV-1 group M transfer to humans occurred in the early 20th 
century, but the first evidence of HIV infection was determined to be from 1959 in the 
Democratic Republic of Congo 11-14. Comparative sequence analysis has revealed that 
HIV-1 group M, which represents the large majority of human HIV infections, is the 
consequence of cross-species transmission of an SIV found in chimpanzees (Pan 
troglodyte troglodyte), SIVcpz (which also includes HIV-1 group N) 15. Further, SIVcpz 
contains a recombinant genome made up of two similar strains of SIV – SIVrcm from 
red-capped mangabeys (Cercocebus torquatus) and SIVgsn from greater spot-nosed 
monkeys (Cercopithecus nictitans) 16,17. Thus, while it was originally believed that 
chimpanzees were a natural host of SIV, we now know they are intermediate hosts with 
increased mortality and morbidity compared to uninfected counterparts 18. Additionally, 
HIV-1 groups O and P likely originated from gorilla SIV transmission, which also appears 
to trace back to chimpanzee SIV 19-21. On the other hand, HIV-2 infection, which is much 
less prevalent relative to HIV-1, originated from a cross-species transmission of SIV 
found in sooty mangabeys (Cercocebus atys), occurring probably around the 1930s 
10,12,22. This strain, also known as SIVsmm, crossed over into the rhesus macaque (RM) 
population during a separate transmission event 23,24. HIV-2 infection displays relatively 
milder symptoms compared to HIV-1, with slower disease progression and less severe 
immunodeficiency 25-27.  
These aforementioned SIV strains are just a handful of more than 40 different 
species-specific SIVs that currently exist in African NHPs [reviewed in 28]. This species-
specificity means that while HIV originated in NHPs, in the majority of cases it is unable 
to effectively replicate in the host it was transmitted from, as a consequence of rapid viral 
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evolution and various host-restriction factors 29-32. For the hosts in which SIV is endemic, 
namely African non-human primates, these animals generally exhibit a normal lifespan 
with high viral loads, but a lack of symptoms 30,33-36. This largely contrasts with non-
natural SIV hosts such as chimpanzees, rhesus macaques and other Asian macaques, 
as well as humans, which tend to progress to the opportunistic infections characteristic 
of AIDS if left untreated 18,37,38. Some of the mechanisms governing the asymptomatic 
nature of SIV in natural NHP hosts have been described 36,39, although additional 
research aims to understand this further for use as a stepping-stone towards a therapy 
and/or cure for HIV.  
 The SIV transmission event from sooty mangabeys (SM) to rhesus macaques, 
briefly mentioned already, occurred during cohousing of these two species in US primate 
centers. The SMs had been infected with SIVsmm prior, and the SM/RM contact initiated 
an outbreak that was first recognized due to pathogenic lymphomas that developed in 
the Asian macaques 23,24. It was this transmission which led to the development of the 
well-known SIVmac251 and SIVmac239 strains now used as a model for human HIV 
infection, since SIV-infected RMs follow a disease course which resembles AIDS 
resulting from HIV 38,40,41. I will describe the SIV viruses used in research in a later 
section, as this is the animal model upon which the entirety of this dissertation is based 
upon. 
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HIV Biology and Disease Pathogenesis 
 HIV and SIV belong to the Retroviridae family, and are more specifically in the 
lentivirus genus 1,2. These lentiviruses have two identical copies of a single-stranded 
RNA genome with nine open reading frames and encode two general classes of 
proteins. These include viral structural proteins (gag, pol, env) and accessory proteins 
(tat, rev, nef, vpr, vif, vpu) [reviewed in 42-44]. It is the envelope (Env) glycoprotein, made 
up of gp41 and gp120 to form gp160, which assists with viral attachment and fusion to 
the cells targeted for HIV infection. More specifically, HIV infects CD4+ T lymphocytes 
and macrophages, and infection and subsequent depletion of the former is the main 
driver towards pathology associated with AIDS. Interaction of Env gp120 and the CD4 
cellular receptor initiates infection, subsequently altering the conformation of gp120, and 
exposing co-receptor binding sites such as the predominant CCR5, and CXCR4, which 
is sometimes seen in chronic infections 45-52. Further, other co-receptors have been 
discovered in addition to CCR5 and CXCR4 53-56, which, in SIV, include CCR2b, CXCR6, 
GPR15, GPR1 and APJ 57-59.  
 HIV infection generally progresses through three phases (Figure 1.1), starting 
with the acute phase, which lasts several weeks. During this time there is a peak in viral 
load and an increase in immune activation, both of which can lead to flu-like symptoms 
60. Mucosal CD4+ T cells undergo a significant decrease and a similar, but less 
pronounced, decrease in seen in peripheral blood (PBMC) CD4+ T cells. The phenotype 
of the mucosal CD4+ T cells, those found in the gut associated lymphoid tissue (GALT), 
tends to lend itself to HIV infection since they are activated and express sufficient CCR5 
to become infected. Mucosal activated memory CD4+ T cells become depleted very 
rapidly and do not experience the slight rebound that is seen in the peripheral blood 
population 61,62. During the chronic phase, which can span many years, there is typically 
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a slow climb in viremia and an opposing drop in CD4+ T cells 63. Most CD4+ T cells are 
lost due to direct infection and subsequent killing, but there is also bystander cell killing, 
as well as immune exhaustion due to chronic activation 64. The onset of AIDS is a 
consequence of a severe drop in CD4+ T cell counts, which was one of the earliest 
observations seen in patients before HIV was identified as the causative agent of AIDS. 
This drop sets the stage for an immune compromised state where opportunistic 
infections can take over 65,66. 
 These aforementioned pathological consequences of HIV were difficult to 
eliminate partly as a result of HIV’s high rate of mutation. This feature is a serendipitous 
attribute for the virus due to the lack of polymerase proofreading, and has led to the 
necessity for highly active antiretroviral therapy (HAART), which is the use of three or 
more antiretroviral (ARV) drugs together. Single ARVs produced drug-resistant strains, 
but consistent use of HAART is able to reduce viral load below detectable levels 67-69. 
There exists a small percentage of HIV-infected individuals that can control infection on 
their own while exhibiting detectable viral loads, called long-term non-progressors, and 
further, a smaller subset of those called elite controllers that have undetectable viral 
loads 70. Trying to understand the mechanisms of control in these individuals, as well as 
certain NHPs including sooty mangabeys (SM) and African green monkeys (AGM) that 
are natural hosts of SIV and do not progress to AIDS (I will touch on the natural NHP 
model more in the next section), is an active field of research 33,35.  
 
 
 
 
 
 
6 
 
 
 
 
 
 
Figure 1.1 – Quantitative and qualitative measures of HIV disease progression. 
Mucosal and blood CD4+ T cell numbers, viremia, and immune activation are shown 
over the course of progression from acute to chronic HIV infection and ultimately AIDS.  
Adapted from Grossman et al., 2006 71. 
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Innate and Cell-Mediated Immune Responses to HIV  
 Most HIV infections are mucosally transmitted, and in approximately ¾ of these 
cases, a single virus or virus-infected cell leads to productive clinical infection 72. The 
genital and rectal mucosa is home to various immunological barriers to HIV. If the virus 
can bypass the thick layer of mucus, which is first line of defense in the female genital 
tract 73, then the next barrier is the mucosal epithelial barrier, followed by the innate 
immune system. The main players in innate immunity to HIV include Langerhans cells, 
dendritic cells (DCs), type I interferons (IFN), cellular restriction factors, and natural killer 
(NK) cells. Langerhans cells express Langerin, a receptor that can capture HIV virions, 
internalize, and then degrade it, thus preventing infection 74,75. DCs express DC-SIGN, a 
receptor that helps DCs capture and internalize, but not degrade, HIV 76,77. DCs then 
carry HIV to the lymph nodes where they can present it to CD4+ T cells, which are the 
main target cell of HIV. Although this promotes infection on one hand, DCs also help 
induce additional immune responses to attempt to eliminate HIV 78. Type I IFNs regulate 
immune activation, apoptosis, and can upregulate cellular restriction factors 
(APOBEC3G, TRIM5a, tetherin), all of which contribute to antiviral activity 79-87. NK cells 
are activated quickly after HIV infection and can mediate effector functions, limit viral 
replication through various methods, two of which include antibody-dependent cellular 
cytotoxicity (ADCC) and antibody-dependent viral inhibition (ADCVI) 88, although these 
functions are likely to only be seen in previously exposed individuals.  
 Compared to innate responses, the cell-mediated responses of the adaptive 
immune system take more time to initiate. Cell-mediated immunity consists of CD4+ and 
CD8+ T lymphocytes that interact with antigens presented to them by antigen-presenting 
cells (APCs) within the context of major histocompatibility (MHC) alleles. After this 
interaction, T cells proliferate and differentiate, eventually maturing from naïve into 
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effector T cells 89. Effector T cells produce molecules that function to kill infected cells, 
either directly or indirectly. Another subset, known as memory T cells, are formed slowly 
after initial antigenic encounter to provide protection after re-infection, at which point they 
multiply rapidly to differentiate into secondary effector and memory populations 90. Within 
the CD8+ T cell population exist cytotoxic T lymphocytes (CTLs), which have been 
associated with an initial drop in HIV viral load after infection 91-93.  CTLs recognize viral 
peptides presented by MHC Class I molecules found on the surface infected cells and 
destroy them. HIV can escape from CTL-induced pressure, and if that escape mutation 
doesn’t lead to a cost in viral fitness, there is a faster progression to AIDS94,95. CD4+ T 
cells have an even wider range of activities compared to CD8+ T cells. They are able to 
differentiate into several subsets, including Th1, Th2, T follicular helper (Tfh), and T 
regulatory (Treg) cells. These subsets carry with them different functions and are 
induced by different conditions 96. CD4+ T cells are heavily depleted in HIV infection, 
particularly in the gastrointestinal mucosa, which can ultimately lead to AIDS 48,97.  
    
Primate Models of HIV and Limitations 
 In general, SIV infection in NHPs can be grouped into those that are pathogenic 
in non-natural hosts (such as RMs) and those that are non-pathogenic in natural hosts 
(such as SMs and AGMs) [reviewed in 28]. SIVmac239 and SIVmac251 are the 
predominant isolates used to infect macaques, as mentioned previously, to model HIV in 
humans. These two isolates are closely related, as SIVmac239 is a clonal virus that has 
a single genotype, which was passaged in vivo from SIVmac251. SIVmac251 is an 
uncloned heterogenous swarm, and was used in the challenge studies we performed in 
Chapter 3 23,98,99. Depending on whom the SIVmac251 was obtained from, it has the 
potential to create slight phenotypic variability as it is actually a collection of unique, 
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albeit very similar, viral stocks. In total, there is up to 2% diversity within the SIVmac251 
pool seen in the US, which may affect the neutralization sensitivity and receptor tropism 
100-102. Within the SIVmac251 swarm, the viruses are still more similar to each other than 
they are to SIVmac239. Even so, the results of SIV challenge studies leading to 
infection, investigating pathogenesis, and vaccine utility are still thought to be an 
incredibly powerful tool when using either of these isolates 41,100.   
 Why did challenging macaques with SIV in order to model human HIV infection 
become so predominant? First, the HIV and SIV viral structures are similar, with 
differences displayed in Figure 1.2. The structural proteins are nearly identical, with 
some variability in accessory genes – namely vpu in HIV and vpx in SIVmac. As 
mentioned above, there is ~2% sequence diversity in SIVmac, although >10% diversity 
is seen in HIV [reviewed in 40,103,104]. As far as disease course and pathogenesis, 
experimental transmission can be modeled after human infection to mimic sexual 
(mucosal) or intravenous (blood) infection, which leads to a dramatic decrease in 
mucosal CD4+ T cells and a less pronounced drop in the blood in both RMs and 
humans. One important distinction is progression to AIDS, which in humans it takes 8-10 
years, while RMs experience a more rapid timeline of 1-2 years. Overall, though, the 
progressive loss of CD4+ T cells systemically, increased lymphocyte turnover, similar 
peak viral loads, chronic immune activation followed by immune exhaustion, amongst 
other shared features, indicate that SIV infection in RMs is the most appropriate model 
currently known for investigating HIV infection in humans 38,105-109.   
 Briefly, non-pathogenic natural SIV infection seen in sooty mangabeys and 
African green monkeys is interesting because it exhibits the same features of high levels 
of viral replication, with viral loads equal to or even greater than what is seen in 
pathogenic RM/human infection 33,35. Unlike pathogenic infection, though, SMs and 
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AGMs do not display chronic immune activation and display more moderate lymphocyte 
turnover 64,110-114. Further, there is no evidence for microbial translocation, which is when 
a breach occurs in the mucosal barrier, which likely leads to chronic immune activation 
115,116. How CD4+ T cells are maintained and progression to AIDS is countered in these 
species is still an active field of research.  
 
 
 
 
 
 
Figure 1.2  Structure of commonly used HIV and SIV strains Schematic 
representation of HIV-1, SIV and chimeric viral genomes. Maroon and blue boxes 
indicate HIV-1- and SIV-derived sequences, respectively. Env, envelope glycoprotein; 
LTR, long terminal repeat; Mm, Macaca mulatta (rhesus macaque); Mn, Macaca 
nemestrina (pig-tailed macaque); SHIV, simian–human immunodeficiency virus; 
SIVmac, macaque SIV; SIVmne, pig-tailed macaque SIV; SIVsmm, sooty mangabey 
SIV; stHIV-1, simian-tropic HIV-1; RT, reverse transcriptase. Figure was adapted from 
Hatziioannou and Evans, 2012 104.  
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Progress in HIV Vaccines 
 Edward Jenner invented the first vaccine over 200 years ago for smallpox by 
inoculating an 8-year old with material from a cowpox lesion taken from another person. 
When challenged later with smallpox, there was no indication of disease 117. Nearly a 
century later in 1885, Pasteur developed the rabies vaccine to be used in humans. He 
was the first scientist to artificially attenuate viruses for use in vaccines 118,119. Since 
then, over 20 vaccines have been developed and regularly used for diseases including 
smallpox, polio, measles, mumps, rubella, and others 119. These generally use a killed or 
attenuated virus, protein, or toxin that induces neutralizing antibodies (nAb) and protects 
from subsequent pathogen exposure by antibody-mediated immunity. Although great 
strides have been made in the decrease or even eradication of certain diseases, the 
worldwide impact of tuberculosis, malaria, and HIV are significant and necessitate 
further research towards a cure.  
In general, there are currently two main approaches towards a vaccine for HIV – 
elicitation of the humoral immune response with broadly neutralizing antibodies (bnAbs), 
and induction of cellular immunity with CD8+ cytotoxic T cells largely directed towards 
conserved epitopes of the virus 120. The focus is on inducing protection through T cells 
because multiple lines of evidence point to CD8+ T cells as vital in the control of HIV 
infection. The first reason is that depletion of CD8+ T cells via antibodies in SIV-infected 
macaques resulted in a dramatic rise in plasma viremia, which was controlled after 
reconstitution of CD8+ T cells 121. Also, the drop in viremia during acute HIV infection 
occurs concomitantly with the generation of HIV-specific CD8+ T cells 122. Further, 
certain human MHC class I alleles found in HIV non-progressors are associated with 
control of HIV and slower progression to AIDS due to highly functional HIV-specific 
CD8+ T cells, relative to non-progressors 123,124. Finally, escape mutations in HIV are 
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known to be a response to immunological pressure on dominantly targeted cytotoxic T 
lymphocyte epitopes 95,125. The ultimate long-term solution to the HIV pandemic would be 
to develop a vaccine that prevents HIV acquisition in the first place (sterilizing immunity). 
A more plausible, but still valuable, alternative may be to lower viral load and thus 
decrease transmission since the risk is greatest when viremia is highest. Beyond those 
options, Picker et al. has recently found that half of the macaques vaccinated with a 
cytomegalovirus (CMV) derived vector encoding SIV genes were able to suppress viral 
load to undetectable levels after repeated rectal SIV challenge. This suppression is likely 
due to the induction of unusual and broad effector memory T cell responses 126,127. The 
same outcome has also been reported after vaginal and intravenous challenge, implying 
that control through the immune response spreads beyond mucosal tissues to the blood 
128.   
The earliest HIV vaccine candidates were subunit vaccines, which include a 
specific antigen shown to be immunogenic and safe, meant to induce nAb responses to 
HIV Env. The first two vaccine candidates were a recombinant gp120 protein and a 
recombinant soluble gp160 with aluminum hydroxide as an adjuvant. To test these 
vaccines, chimpanzees were immunized 3x (0, 1, 8 months) with one of these vaccines, 
then challenged intravenously 35 weeks after immunization. Two animals were 
vaccinated with each candidate, and only the recombinant gp120 vaccine showed 
protection. Therefore, it moved on to phase I clinical trials where 50 human volunteers 
were immunized and sera from almost all of the vaccine recipients neutralized at least 
one lab-adapted HIV-1 strain (but not primary HIV-1 isolates) 129. With this outcome, this 
AIDSVAX vaccine moved on to phase II and phase III testing by VaxGen. These were 
double-blinded, placebo-controlled clinical trials in two sites. First, Vax003 in Thailand 
recruited 2,546 intravenous drug users and combined a clade B and clade E adjuvanted 
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recombinant gp120 together (AIDSVAX B/E) 130. Subjects were vaccinated seven times, 
but showed approximately the same amount of infections in placebo (105 infections) and 
vaccine (106 infections) groups and thus demonstrated no protection or effect on viral 
load 131. The second study, Vax004 used two different isolates of clade B viruses and 
was tested among 5,400 people at risk of sexual HIV transmission in the US, Canada, 
Puerto Rico and the Netherlands (of which ~90% were men who have sex with men). 
Participants were again vaccinated seven times, but the trial showed no evidence of 
protection (241 vaccine group and 127 placebo group infections) or reduction in viral 
load, although non-neutralizing HIV antibodies were elicited 132.    
Despite the lack of success in these AIDSVAX trials, a later study known as the 
RV144 ‘Thai’ trial used the ALVAC-based (canary-pox) vaccine, in combination with the 
AIDSVAX gp120 vaccine as the protein boost. It showed 31.2% efficacy against HIV 
infection in a low-risk heterosexual population in Thailand. This was a large phase III 
HIV-1 vaccine trial that used a canary-pox vector expressing gag, protease, and Env 
proteins and immunized volunteers at weeks 0, 4, 12 and 24. The 12 and 24 week time 
points also included an AIDSVAX B/E gp120 (used in the previous Vax003 trial) as a 
boost. While >16,000 people participated in the study, approximately 4,000 of those 
were excluded since they did not receive all four immunizations. Once these volunteers 
were removed, the vaccine efficacy was found to be statistically insignificant. But a 
“modified intent to treat (mITT)” analysis was statistically significant, with the 31.2% 
efficacy previously mentioned. Interestingly, it appeared that only CD4+ T cell and gp120 
non-neutralizing antibody responses were generated after giving the viral vector-based 
vaccine, with very low levels of both CD8+ T cell and neutralizing antibody induction 133.  
Numerous vaccine platforms have been studied, including adjuvanted protein 
vaccines 134, virus-like particles (VLPs) 135, plasmid vectors 136-141, viral 142-146 and 
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bacterial recombinant vectors 147,148. As for the viral recombinants, there are an 
expansive amount of them, including those that are based on poxviruses (such as 
modified vaccinia Ankara (MVA) 142, vaccinia virus 144, AAV 146, VSV 149, measles-virus 
based vaccines 143, and different Ad vectors 145 (which I will expand on in upcoming 
sections of this thesis). In addition to RV144, vaccine regimens including MVA and 
NYVAC, which all encode SIV proteins, have only exerted modest levels of control over 
SIVmac251 replication 150. In many HIV vaccine trials, prime-boost strategies are often 
employed to increase the HIV antigen-specific immune responses, and allow for reduced 
vaccine dosage to minimize toxicity. These often combine DNA or protein vaccines, or 
use heterologous viral vectors 147,148. DNA vaccines, such as those being pursued by 
Weiner et al., have potential since they induce both cellular and humoral immunity 
potently 151, though they are typically used in combination with another modality 152,153.  
 
Adenoviruses and Their Use As HIV Vaccine Vectors 
 Adenoviruses (Ad) have been used for three decades in gene therapy, and now 
are used in the development of vectors for HIV, malaria, and hepatitis C vaccines, as 
well as tumor therapies. Ad-based vectors have shown superior immunogenicity, 
particularly in CD8+ T cell induction. They can be derived from bacterial molecular 
clones, and are thus easily modified 154. Adenovirus is icosahedral, non-enveloped, and 
the capsid contains a double-stranded, linear DNA genome of ~34-43 kb 155 (Figure 
1.3). The capsid faces are composed of 240 hexons, each with three identical proteins, 
and 12 pentons sit on the vertices, each with five protein chains. A long fiber extends 
from each vertex, made up of three identical chains that form a knob at the end 156-158. 
The hexon protein contains seven hypervariable regions, though the remaining ~80% of 
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the hexon sequence is conserved between Ad serotypes 159-161. The genome contains 
two inverted terminal repeats, with early (E1A, E1B, E2-E5) and late transcription (L1-
L5) genes. When Ad infection occurs, E1a is expressed and encodes polypeptides that 
initiate transcription of other early genes 162,163. Thus, the most common way to make Ad 
replication-incompetent is to delete E1a – which is considered a safer alternative to 
replication-competent vectors 164,165. Another common deletion performed in order to 
make more space for transgenes is the E3 domain, a region that encodes polypeptides 
that subvert the immune response, although this deletion on its own does not render it 
replication-incompetent 166. Studies have shown that whether E1-deleted alone, or E1- 
plus E3-deleted, there does not appear to be a variation in vector infectivity, or an effect 
on the vector’s ability to induce transgene product-specific CD8+ T cell responses 167.  
 Adenoviruses are classified in the genus Mastadenovirus, which currently 
contains 7 known human adenoviral species classified into 7 subgroups, A-G 168. 
Although human Ads were historically further broken down into 51 serotypes based on 
hemagglutination and serum neutralization reactions, there now exist 65 serotypes 
based on genomic data 169-176. In the past few years, a New World monkey Ad was able 
to cross into humans to cause infection 177. Adenovirus can cause respiratory disease, 
conjunctivitis, and gastroenteritis, and as such, subgroups tend to be associated with 
tissue tropism since unique cellular receptors are expressed in different parts of the body 
178. The main receptors used for viral binding and entry are CD46 for group B Ads, and 
the coxsackie adenovirus receptor (CAR) for nearly all the other serotypes including 
human adenovirus type 5 (HAdV-5) 179. The Ad fiber protein “knob” engages cells 
through interaction with CAR, which is found in numerous tissues including the heart, 
brain, pancreas, intestine, lung, liver, testis and prostate 180-182.  
 When adenoviral infection occurs, Ad-infected macrophages and dendritic cells 
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transport Ad to lymph nodes present antigen, which leads to adaptive immune 
responses. These include CD8+ cytotoxic T cell (CTL) responses to viral proteins and 
vector-encoded transgene products expressed by transduced cells, and production of 
antibodies against capsid proteins by B cells 183. If the individual has previously 
encountered Ad, primed memory CD8+ T cells will recognize antigen-expressing tissue 
cells and rapidly eliminate them 184. This is one difficulty, which I will discuss in more 
detail later, with the use of the same vector to boost or re-challenge, since circulating 
neutralizing antibodies prevent virus transduction and memory T cells decrease 
transgene expression.  
 Despite this, there are numerous features of Ad that make it an attractive 
candidate for a vaccine vector. These include ease of manufacture (Ad does well in 
large-scale cell culture), good safety profile, and the ability to elicit broad immune 
responses. Ad is able to target the mucosa, and infect and persist in a wide variety of 
both dividing and non-dividing cells 185,186. The transgene can be expressed at a high 
level, induce strong chemokine and cytokine responses, all without integration of the 
viral genome into the host genome which would carry the risk of insertional mutagenesis 
187. Immunogenicity testing with Ad vectors in mice, NHPs, and humans have shown 
induction of potent and sustained transgene product-specific CD8+ T cells, which is 
likely a consequence of Ad persistence in general 185,188-190. Persistence occurs largely in 
activated T cells, where Ad vectors continue to be transcriptionally active, leading to 
more activation and preventing contraction of vector-induced T cells. On one hand, this 
is advantageous, as it creates high frequencies of effector/effector memory T cells, but 
it’s also possible that the extended availability of activated CD4+ T cells can increase 
susceptibility to HIV by increasing target cell infection. Furthermore, it’s possible that the 
greater presence of effector/effector memory CD8+ T cells may hinder the development 
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of central memory cells, which proliferate faster upon antigen re-exposure 191.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Adenovirus structure 192 
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Adenoviral Pre-Existing Immunity 
 Levels of pre-existing immunity to adenovirus varies among the serotypes, and 
between different populations worldwide. Humans are infected frequently with Ad viruses 
throughout their life, and as expected, greater exposure occurs with age. In the United 
States, between 40-60% of people carry detectable neutralizing antibodies (nAbs) to 
HAdV-5, and this figure is much higher in developing countries 193. Ad-specific nAbs are 
directed against the hexon loops and are serotype-specific. High levels of nAbs can 
significantly influence the immunogenicity of the vector as it can restrict the number of 
HAdV-5 particles that can infect target cells and produce transgene-derived protein 
products. This leads to lower levels of antigen presentation, thus decreased adaptive 
immune responses 194. The high levels of human anti-HAdV-5 antibodies, especially in 
sub-Saharan Africa, are likely part of the difficulty encountered with HAdV-5-vectored 
HIV vaccines. Further, even if nAbs are not present initially, most vaccine strategies 
involve at least one booster to amplify memory T cells, which may be hindered by nAbs 
that developed during the prime 195.  
In addition to concerns about nAbs, T cell responses also pose a difficulty with 
AdV vector immunization due to broad cross-reactivity. Human AdV epitopes have been 
found in both CD4+ and CD8+ T cells. In individuals previously exposed to AdV, 
anamnestic AdV-specific CD8+ T cells initially take over the response to AdV vectored 
vaccines. These pre-existing HAdV-5-specific CD8+ T cell responses are capable of 
reducing the potency and breadth of vaccine-induced HIV-specific CD8+ T cell 
responses 196-201 and this reduction in transgene-specific responses by AdV-specific T 
cells has been shown to occur in cross-reactive serotypes 196. Previous work from our 
lab has found that AdV-reactive T cells possess an effector and effector memory-like 
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phenotype. Ad-specific CTLs largely produce effector functions such as MIP1D and 
perforin, which may indicate efficiency in targeting and eliminating vector-infected cells 
to decrease vaccine efficacy 202. There are 65 known strains of human adenovirus, and 
at least 25 non-human primate strains 203-206, so it is likely that AdV-specific T cell 
memory and cross-reactivity may affect more rare serotypes, in addition to common AdV 
serotypes 207. Therefore, trepidation towards the use of rare AdV vectored vaccines may 
still be warranted. Furthermore, human intestinal tissue, particularly intestinal 
lymphocytes, can frequently be found to harbor adenoviral DNA 206 and captive 
macaques are chronically infected by adenoviruses 208. Adenovirus has been shown to 
persist for years in humans, and replication-defective HAdV-5 vectors can persist over a 
year in mice 185,209, potentially resulting in prolonged antigen presentation and stimulation 
of T cells at a common site of entry for HIV.  
 
Step Trial and other AdV Vectored Clinical Trials for HIV 
 Adenoviruses have contributed to a significant proportion of viral vector-based 
HIV vaccine trials partially due to the high-frequency CD4+ and CD8+ T cell responses 
they stimulate. Most other viruses used as vaccine vectors have proven to be less 
immunogenic than AdV-based platforms, including adeno-associated virus (AAV), 
vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), herpes 
simplex virus (HSV), semliki forest virus (SFV), Venezuelan equine encephalitis virus 
(VEE), and others 191. Despite the initial positive anticipation for AdV vectored vaccines 
for HIV, the outcome of several studies, including the Step Trial, have been 
unsuccessful. This has raised many questions as to why the vaccine regimens failed, the 
usefulness of cellular immune responses as HIV vaccine targets, and the predictive 
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efficacy of NHP models.   
Prior to pursuing human trials for AdV vectored vaccination, AdVs have had a 
three-decade history of development in gene therapy. Before the Step Study, several 
primate challenge studies were conducted to investigate the efficacy of a recombinant 
HAdV-5-based HIV vaccine. AdV-vectored vaccines have consistently induced strong 
cell-mediated immune responses and have thus been prime candidates for further 
development. An early pre-clinical study by Merck compared several vaccine vectors 
that encoded SIV gag. These vectors included DNA, a modified vaccinia Ankara virus 
vector, and a replication-incompetent HAdV-5 alone or in combination with the DNA 
vector. Results demonstrated the largest percentage of gag-specific CD8+ T cells were 
induced by either HAdV-5 alone or with the DNA prime. 188. The HAdV-5 encoding only 
gag led to substantial and durable control of SHIV-89.6P, but it appears that SHIV-89.6P 
might not be the most appropriate virus to use for modeling human HIV infection 210,211. 
This strain has a different target cell tropism and pathogenesis than most SIV/HIV 
strains as it causes rapid CD4+ T cell depletion. Additionally, all macaques were Mamu-
A*01 positive, an MHC class I allele which is known to be naturally protective in SIV 
infection, so make-up of the NHPs was likely not representative of a human population 
212-214. Another study vaccinating with HAdV-5 encoding gag and subsequently 
challenging with a single high-dose of the CCR5-tropic SIVmac239 clone led to transient 
viral control, but only in Mamu-A*01 positive macaques 215. An analogous outcome 
occurred when a trivalent HAdV-5 vaccine was tested in another group of Mamu-A*01 
positive macaques and challenged with SIVmac239 216. Further challenge studies prior 
to Step believed that including more viral proteins and/or a DNA prime could induce 
protection 217-219.  
Despite what seems to be, in retrospect, less than conclusive evidence for 
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moving towards a human Phase 1 study, a trial using an IM-administered trivalent 
HAdV-5-based HIV vector expressing gag, pol and nef was initiated in May 2003 220. 
These proteins are relatively well conserved across different HIV clades and recognized 
by many infected individuals. Phase 1 studies are designed to test dose safety and 
immunogenicity, so study participants received between 3x106 – 1x1011 viral particles 
(vp) of vector at week 0, 4, and 26, with no serious adverse effects following vaccination. 
Nearly ¾ of subjects had HIV responses at week 30 until week 78. Based on these 
results indicating safe and robust immune responses, a phase IIb proof-of-efficacy trial 
called Step began to enroll subjects at high risk for HIV-1 infection in 2004. 
The Step Study was a multi-center, randomized, double-blind and placebo-
controlled study with enrollment sites including North America, South America, the 
Caribbean, and Australia, where clade B HIV-1 is predominant. The study population 
was HIV-negative when enrolled and included mostly men who have sex with men 
(MSM) and heterosexual women at high risk for HIV acquisition. It used the same 
replication-defective recombinant HAdV-5 vector as in the Phase 1 study to target the 
induction of T cell responses against HIV proteins. This was the first large-scale study to 
assess the efficacy of a T cell-based HIV vaccine, with 3,000 participants split in half 
between vaccine and placebo recipients. Since it appeared that pre-existing AdV 
seropositivity did not limit vaccine efficacy in the Phase 1 study, both HAdV-5 
seropositive and seronegative subjects were equally included in the Step Study. As 
before, participants were immunized at weeks 0, 4, and 26, using an optimized dose of 
3x1010 vp. The goal was to either prevent infection, or control viral replication after 
infection in order to limit pathogenesis and reduce secondary transmission 221.   
Unfortunately, despite early optimism, the study was prematurely halted during a 
planned interim analysis in September 2007. It was revealed that the vaccine regimen 
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was unable to prevent infection or lower viral replication in vaccinated individuals. Even 
worse, by spring of 2008, the placebo group had 33/922 infected men versus 49/914 
men in the vaccine group, a statistically significant increase in HIV acquisition in the 
vaccinated individuals. Viral set points initially revealed no significant difference between 
placebo and vaccine recipients. Further analyses indicated a trend towards HIV 
acquisition in those with pre-existing HAdV-5 neutralizing antibodies – for titers <18; 
20/382 vaccinated men versus 20/394 placebo controls became infected, and in titers 
>18; 21/392 vaccinated men versus 9/386 placebo controls became infected. Beyond 
that, circumcision was shown to lower the risk of HIV infection. It is important to note, 
though, that nAbs to HAdV-5 prior to vaccination were lower in circumcised men 221,222.  
Another Phase IIb clinical efficacy trial for HIV commenced in South Africa 
around the same time called Phambili where clade C is predominant. This study tested 
individuals with both low and high pre-existing HAdV-5 titers at high risk for HIV-1, 
although the predominant mode of transmission was via unprotected heterosexual sex. 
In light of the Step Trial interim reports, this study was halted and unblinded in 
September 2007, with many subjects not having received the full complement of vaccine 
doses. In total, 801 participants had been enrolled, 11 HIV-infections were confirmed 
(10/11 were women), with 4 in the placebo group and 7 in the vaccine group. 
Participants with HAdV-5 nAb titers >18 revealed 6 vaccinated-group HIV infections 
versus 3 in the placebo-group. These aforementioned differences in vaccine and 
placebo group infections were only trends, and not significant differences 223,224.  
Despite the lack of efficacy seen in both Step and Phambili, another HAdV-5-
based vaccine advanced to a clinical trial in 2009 called HVTN 505. This study initially 
aimed to examine the vaccine’s ability to moderate the course of HIV infection after 
vaccination. Once enrollment began, researchers decided to also detect the efficacy of 
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preventing HIV acquisition during the first 18 months after a completed vaccination 
course. HVTN 505 used the Vaccine Research Center’s multi-clade HIV-1 DNA plasmid 
(EnvA, EnvB, EnvC, gagB, polB, nefB) and boosted with recombinant HAdV-5 (EnvA, 
EnvB, EnvC, gag/polB). They enrolled 2,504 HAdV-5 seronegative, circumcised MSM in 
order to attempt to prevent the risks seen in Step and Phambili. In April 2013, this study 
followed the fate of previous HAdV-5-vectored HIV vaccines and was stopped. The Data 
Safety Monitoring Board revealed statistical futility, meaning there was no chance that 
the vaccine would prevent HIV acquisition or lower viral load set-point in those who 
became HIV infected after vaccination. At this time, there were 71 cases of HIV (41 
vaccine-group, 30 placebo group) and 48/71 of those occurred after 28 weeks when the 
vaccine regimen was already completed.  It is important to keep in mind that of those 48 
infections where participants actually received the intended immunization course (27 
vaccine-group and 21 placebo-group), there was no statistical significance between 
groups 225. Follow-up of the HVTN 505 study participants is currently underway.  
 
Theories for the Step Study Failure  
Why did these trials fail and were the outcomes potentially predictable? Although 
the results of these trials are disappointing, prior analogous SIV vaccine studies in 
rhesus macaques had not been able to show long-lasting protection. One proposed 
hypothesis for the lack of efficacy seen in Step was the inability for the series of vaccines 
to elicit sufficiently broad immune responses for the variety of HIV strains in circulation. 
Although the vaccine was shown to be immunogenic in 75% of participants, vaccinated 
individuals made a median of only one CD8+ T cell response per protein when using 
pools of vaccine-matched 9-mer peptides 221,222,226. This narrow breadth seems too 
modest to handle the extensive variability of circulating HIV strains 227,228. As already 
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mentioned, vaccination with a viral vector induces vector-specific neutralizing antibodies. 
Any pre-existing immunity to AdV can restrict the number of HAdV-5 particles that can 
infect target cells, and also limit both magnitude and breadth of cellular responses to the 
HIV gag, pol, and nef antigens being delivered 220,222. Further, homologous prime-boost 
regimens with viral vectors are suboptimal compared to heterologous prime-boost 
regimens, since individuals who may have been seronegative at the start of the trial 
develop vector-specific nAb after the first immunization leading to anti-vector immunity 
195,229. Therefore, during the Step Trial, all participants would have been exposed to 
HAdV-5 after the first vaccination, hypothetically producing an equal likelihood of 
targeted nAb and T cell responses. Another proposed hypothesis to explain the 
increased HIV acquisition is the activation of dendritic cells through immune complexes 
composed of HAdV-5 particles and HAdV-5-NAbs, which may facilitate HIV infection of 
DC and spreading to CD4+ T cells at the site of virus entry, such as mucosal surfaces 
230. However, again, Step Study vaccine recipients that were baseline HAdV-5 
seronegative would develop HAdV-5 nAb after the first vaccination. Most enrolled 
individuals received the complete course of three immunizations, thus all vaccinees 
should show evidence of HAdV-5 seropositivity and thus increased risk of HIV infection.  
Only peripheral blood mononuclear cells (PBMCs) were collected during the Step 
Trial, and no baseline samples were obtained 221. Data from two studies among Step 
participants (both of which also did not have access to mucosal samples) concluded that 
HAdV-5 specific CD4+ T cells were unlikely to be responsible for increased HIV 
susceptibility 231,232. In one, the presence of pre-existing HAdV-5 nAbs was shown to not 
predict the presence of HAdV-5-specific CD4+ T cells both before and after vaccination. 
Also, HAdV-5-specific CD4+ T cells in HAdV-5 seropositive and seronegative individuals 
expanded after HAdV-5 vector immunization, and HAdV-5 seronegative patients all 
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converted to HAdV-5-seropositive after the first vaccination 231. The second study used 
the Step Study HAdV-5 vaccine and found no evidence of CD4+ T cell activation after 
vaccination. It showed that HAdV-5-specific nAbs before vaccination did not correlate 
with HAdV-5-specific cellular immune responses. It also said that HAdV-5-specific T cell 
responses after vaccination were lower in HAdV-5 seropositive individuals compared to 
HAdV-5 seronegative ones 232.  
Thus, although multiple theories have been considered and tested in attempts to 
understand the failure of the Step Study, the main one I will argue for in this dissertation 
is the influence of activated mucosal CD4+ T cells on HIV acquisition. In those subjects 
with previous exposure to adenovirus, whether it be HAdV-5 or another strain to which T 
cells are cross-reactive, immunization with a HAdV-5 vector will cause memory AdV-
specific CD4+ T cells to become activated. Since AdV is a fecal-oral pathogen, activation 
of these memory cells will cause trafficking to the gastrointestinal mucosa, which is the 
primary site of initial HIV encounter and subsequent infection 233. A greater frequency of 
CD4+ T cell targets that are activated and largely express the co-receptor CCR5 would 
hypothetically increase the risk of HIV acquisition, as shown in the model below (Figure 
1.4). Benlahrech et al. had previously proposed that increased rates of HIV infection in 
the Step Study are due to activation and expansion of HAdV-5-specific mucosal-homing 
memory CD4+ T cells. They found that memory CD4+ T cells from HAdV-5 seropositive 
subjects cultured for 5 days with HAdV-5 pulsed DCs preferentially expanded AdV-
specific memory CD4+ T cells expressing D4E7 integrins, CCR9 and CCR5, which 
indicated a mucosal homing phenotype 234. Investigation of T cells within the mucosa, 
though, still provides the most reliable method of determining T cell phenotypes within 
this compartment, since previous studies have shown no increase in D4E7 in peripheral 
 
26 
blood CD4+ T cells from vaccinees in the Step Study 231.     
 
 
       
 
Figure 1.4 A. Natural exposure to Ad will create cross-reactive AdV-specific CD4+ T cells that are 
activated upon AdV-based vector vaccination. B. These activated CD4+ T cells will traffic to the GI mucosa, since Ad is naturally found 
there due to fecal-oral transmission. 
C.  Those at high risk for HIV infection due to sexual practices may have come in contact 
with HIV and the larger concentration of preferential CD4+ activated T cell targets in 
the GI mucosa can increase HIV susceptibility.  
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Figure 1.4 Model for AdV-based vector vaccination induced HIV acquisition 
 
 
 
 
 
 
Use of Alternative Adenoviral Serotype Vaccines 
 In light of the evidence against using HAdV-5 for an HIV vaccine, researchers 
have started leaning towards other adenovirus serotypes with lower seroprevalence. 
These are viewed as promising since the rare frequency would hypothetically lead to 
lower rates of pre-existing immunity, although cross-reactive T cell responses may still 
hinder use of rare serotypes. There are biological differences, too, between Ad 
serotypes 229, including in vivo tropism 235, use of different cellular receptors 236, 
interaction with dendritic cells 237,238, innate immune profiles 239, and adaptive immune 
phenotypes 240. Some options for alternative serotypes are HAdV-11, HAdV-24, HAdV-
26, HAdV-28 HAdV-35, which are all less common worldwide with lower titers of pre-
existing nAbs compared to HAdV-5 (subgroup C). For HAdV-26 (subgroup D) and 
HAdV-35 (subgroup B), they are rare in the States and SE Asia, and are lower than 
HAdV-5 in Africa. Also, relative to HAdV-5, HAdV-26 and HAdV-35 induce significantly 
higher innate cytokine responses in vivo, but some studies indicate that they are less 
potent as vaccine vectors in mice and NHPs, with a lower protective efficacy in NHPs. 
Nonetheless, these rare Ad vectors have moved on to human trials 236,241-244.  
 A recent Phase 1 dose-escalation study using a HAdV-26-based vector HIV 
vaccine containing EnvA was demonstrated to elicit transgene- and vector-specific 
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responses that persisted for at least 1 year post-vaccination 245. They saw a dose-
dependent expansion of the magnitude, breadth, and epitopic diversity of Env-specific 
binding antibody responses. Further, they observed antibody-dependent cell-mediated 
phagocytosis, virus inhibition, and degranulation. The vaccine induced Env-specific 
cellular immune responses in both CD4+ and CD8+ memory T cells, albeit with a limited 
breadth 246. Interestingly, baseline vector-specific T cell responses did not impair Env-
specific immune responses in this study and other HAdV-26-based HIV vaccines 245.  
 Similarly to HAdV-26, HAdV-35 has a low seroprevalence, with only 2-16% of 
individuals exposed worldwide 247. Preclinical studies using heterologous vectors and 
gene inserts with HAdV-35 and recombinant MVA have shown reasonable cellular 
immune responses 248. A Phase 1 dose-escalation study using a 1) HAdV-35 with HIV-1 
subtype A gag, RT, integrase, and nef and 2) HAdV-35 with EnvA were both well-
tolerated and immunogenic in >90% of participants 249. Despite these results, HAdV-5 
and HAdV-35 share ~90% hexon sequence homology, which would predict that cross-
reactive T cells may hinder protection from HIV 250. Nonetheless, additional studies, 
including a HAdV-26/HAdV-35 prime-boost phase 1 study and others are ongoing.  
 Non-human primate Ad vectors are also being pursued for possible use in HIV 
vaccines, in particular, chimpanzee Ad (AdC) vectors. AdC vectors are attractive in that 
they have low or no seroprevalence in humans (0-4% in US, up to 20% in developing 
countries) 193,251,252, have low nAb titers in humans (<10% of those with AdC nAb have 
titers >200), can grow in human cell lines including HEK 293 and PerC6 cell lines, and 
exhibit similar immunological potency to HAdV-5 and HAdV-6 in mice and NHPs 253,254. 
In NHP, vaccination with AdC vectors has displayed long-lived responses persisting over 
5 years 253. In pre-clinical studies, AdC-based vector vaccines were able to protect from 
Ebola virus 255, influenza 256, malaria 257, and so it appears that their development as HIV 
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vectors will remain to be seen. Recent studies of prime-boost immunizations with AdC 
serotypes 6 and 7 as vectors expressing SIV Gag/Tat have induced robust T cell 
responses, although without significant protection from SIV transmission. Notably, 
breakthrough infections in macaques that were AdC7 followed by AdC6 SIV vector-
immunized has a significant, but transient, reduction in set-point viral load relative to 
unvaccinated controls 258. These two AdC vectors appear to be moving forward in clinical 
trials.  
Interplay of Mucosal Immunity and T Cell Phenotype During HIV Infection  
 The mucosal surface of the gastrointestinal tract (GI) is often the initial site of HIV 
exposure in men who have sex with men (MSM) and a major site of HIV replication. The 
anatomical and physiological characteristics of the GI tract, including its function as a 
barrier to the outside world and the source of most of the body’s T cells 259, has led to a 
boom of research interest which is just starting to illuminate the unique immunology of 
this site. HIV infection leads to loss of CD4+ T cells systemically, but the most striking 
depletion is of the lamina propria CD4+ T cells during acute infection, which does not 
rebound effectively like the peripheral blood and over time can lead to AIDS-related 
pathologies 260-262.  
It was the initial observation of enteropathy seen very quickly after HIV infection 
that led to an interest in what was occurring at the mucosal surface 263. One possible 
cause for HIV enteropathy appears to be activation in the gut 264-266. Proinflammatory 
mediators including beta-chemokines 267, IL-6, IL-10 and IFNg 268 are found at high 
levels in the lamina propria of HIV-positive individuals. Also, studies have shown that the 
degree of GI inflammation correlates with viral replication 260,262,268. The principal 
hypothesis for the systemic immune activation seen with HIV stems from initial damage 
to the tight epithelial barrier of the GI mucosa, leading to bacterial translocation and their 
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microbial products stimulating the immune system. In turn, the increased levels of 
inflammation lead to increased CD4+ T cell activation and create more targets for HIV 
115,269. Immune activation is actually a better predictor of disease progression than either 
peripheral blood CD4+ T cell count or plasma viral load 270. Notably, the majority of T 
cells in the GI mucosal tissues of healthy individuals express the HIV co-receptor CCR5, 
furthering their permissiveness to infection 271,272. In fact, HIV infects CD4+ T cells in the 
gut mucosa 10-fold more frequently than CD4+ T cells in the peripheral blood 273,274. To 
develop a successful HIV vaccine, it appears that we would need to prevent early CD4+ 
T cell loss within the gastrointestinal tract, preserve barrier integrity, and develop a better 
understanding of the complex mucosal microenvironment in general. 
Polyfunctional HIV-specific CD8+ T cells, in both the peripheral blood and GI 
mucosa, are probably one aspect of a successful HIV vaccine 121,125,275. When measuring 
the functional capacity of HIV-specific CD8+ T cells in the peripheral blood of HIV-
positive individuals, it was found that those CD8+ T cells that were able to control viral 
replication were producing several effector cytokines (IFNg, MIP-1b, TNFa, IL-2, and/or 
CD107a). Since polyfunctionality was seen to be lost in the peripheral blood with 
progressive chronic infection, this led to studies investigating SIV/HIV-specific T cells in 
the mucosa 276. Similarly to the blood, these cells in the mucosa were limited in 
functionality during chronic HIV infection. Several rhesus macaque studies have further 
illustrated vaccine-induced functional SIV-specific CD8+ T cells in the GI mucosa, the 
frequency of which negatively correlated with peak plasma viral load after SHIV 
challenge 277-279. This leads one to believe in the benefit of an HIV vaccine that induces a 
polyfunctional CD8+ T cell response.    
Although it is clear that some similarities exist between T cells in the peripheral 
blood and those in the intestinal mucosa, this thesis will emphasize that drawing 
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conclusions from the latter based on the former is not always warranted. One variable 
may be the magnitude of a T cell response, where several functions are commonly 
measured. Most often, IFNg expression is the gold standard assay, but IFNg alone will 
typically underestimate the magnitude of the response 280-283. In this thesis, IFNg, TNFa, 
and IL-2 were combined to assess Ad-specific T cell responses. IFNg and TNFa are 
both pro-inflammatory cytokines with immunomodulatory and anti-viral effects 284. IL-2 is 
a cytokine-signaling molecule required for the growth, proliferation, and differentiation of 
T cells to become effector cells and generate immunologic memory 285.  
Another potential difference between mucosal and peripheral blood T cells may 
be the expression of activation markers. As mentioned, HIV preferentially infects 
activated CD4+ T cells, and we used the well-established activation markers HLA-DR, 
CD25, CD69, and Ki67 to understand compartmental differences. HLA-DR is an MHC 
Class II cell surface receptor with the primary purpose of presenting peptide antigens to 
T cells, which leads to T cell responses. In addition to this, the frequency of MHC-II+ 
CD4+ T cells increases after T cell activation, resulting in HLA-DR being regarded as a 
marker of activation 286. CD25 is the alpha-chain of the IL-2 receptor, a trans-membrane 
protein present on activated T and B cells 287,288. CD69 is the earliest inducible cell 
surface glycoprotein acquired during lymphoid activation, and is involved in lymphocyte 
proliferation 289. Finally, Ki67 is a nuclear antigen that is a cellular marker of proliferation 
and is absent in resting cells 290.  
 
Developing a vaccine-induced SIV acquisition model using a low-dose challenge 
 In order to determine whether vaccination with a species-specific AdV vector 
increases susceptibility in RMs to SIV infection through induction of CD4+ T cell 
activation in the rectal mucosa, we designed a model using a low-dose intra-rectal SIV 
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challenge. In this thesis, I show evidence for increased AdV-specific CD4+ memory T 
cells and activated CD4+ memory T cells in the rLPL after AdV vector vaccination. 
These changes in CD4+ memory T cells were evident as early as 2 weeks and gradually 
contracted by 16 weeks after AdV-vector vaccination. This led to the development of a 
RM model that aimed to determine if AdV-induced activation levels are sufficient to 
increase SIV susceptibility. To clarify this question, it was necessary to titrate SIV to a 
very low dose that would generally be insufficient to infect animals when administered 
intra-rectally. The titration is described in Chapter 3, which used SIVmac251 at a 
beginning dose of 1:5000 or 4TCID50 and was tested in 15 macaques. Prior to this, 
titration data on this stock of SIVmac251 only used a few macaques, which produced 
fairly inconclusive results. Using our titration results, the AdV vector vaccine study set-up 
would demonstrate activation-induced susceptibility to SIV if more vaccinated animals 
became infected at the same dose as placebo controls. Our biggest hurdle in the design 
of this study was to synchronize the window of increased CD4+ T cell activation we 
expected to see in the AdV vector vaccine group with the intra-rectal challenges. This 
feat was complicated, as the rectal mucosa required a few weeks to heal properly after 
biopsies, prior to initiating intra-rectal SIV challenges. Therefore, we were only able to 
obtain a single week 2 post-vaccination rectal biopsy time point, in order to begin SIV 
challenges by week 5. We recognize that immunological dynamics might be slightly 
different in macaques obtained from different sources and housed in different settings, 
thus we risked missing the ability to collect rLPL samples during the CD4+ memory T 
cell activation in order to begin SIV challenges within the desired timeframe. 
Unfortunately, at n=10/group, our statistical power was very limited, and a similarly 
designed study with larger macaque numbers may be able to produce a statistically 
significant outcome, rather than just the trend we were able to show. 
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Thesis goals 
 The failure of the Step Study, and the consequent halting of Phambili and HVTN-
505, demonstrated that HAdV-5 vectors were not attractive candidates for HIV vaccines. 
Further, the presence of pre-existing AdV-specific immunity resulted in an increased risk 
of HIV acquisition, and a myriad of studies have sought to investigate the mechanism for 
this risk. In this thesis, I advocate for the use of the rhesus macaque as a model that will 
optimally become increasingly refined in future studies. Unlike previous studies that 
employed a human AdV vector in macaques to simulate vaccination with AdV vectors in 
humans, we argue that using a macaque-specific AdV vectored vaccine (based on 
SAdV-7) is a more appropriate model. Also, obtaining samples from the peripheral blood 
alongside the rectal lamina propria offers insight into the unique immunology of the 
gastrointestinal mucosa. This method can clarify previously disputed assumptions based 
on PBMC data alone. The rhesus macaque model allows us to characterize the 
phenotype and functionality of CD4+ T cells in various compartments with frequent time 
points, which leads to a greater probability of detecting rapidly changing immunological 
dynamics. We hypothesized that AdV-based vector vaccination would result in increased 
AdV-specific CD4+ memory T cells and activated CD4+ memory T cells in the rectal 
mucosa, which we successfully demonstrated together with a lack of significant changes 
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in the peripheral blood. Further, we used these results to design a SAdV-7 vectored 
vaccination followed by a low-dose intra-rectal SIV challenge study to determine whether 
AdV vectored vaccination leads to activation-induced susceptibility to SIV. We were able 
to show a trend towards SIV acquisition in the vaccine group, while also initiating the first 
step towards developing a vaccine-induced SIV acquisition model using a low-dose 
challenge. These studies have established the groundwork for use of macaques as a 
valuable tool to further enhance pre-clinical understanding of HIV vaccine dynamics.   
CHAPTER 2 
Increased Mucosal CD4+ T cell Activation Following Vaccination With an 
Adenoviral Vector in Rhesus Macaques 
 
Irene Bukh, Roberto Calcedo, Soumitra Roy, Diane G Carnathan, Rebecca Grant, 
Qiuyue Qin, Surina Boyd, Sarah J. Ratcliffe, Christin L. Veeder, Scarlett L. Bellamy, 
Michael R. Betts, and James M. Wilson 
 
 
Abstract 
The possibility that vaccination with adenoviral (AdV) vectors increased mucosal 
T cell activation remains a central hypothesis to explain the potential enhancement of 
HIV acquisition within the Step trial. Modeling this within rhesus macaques is 
complicated because human adenoviruses, including adenovirus type 5 (HAdV-5), are 
not endogenous to macaques. Here, we tested whether vaccination with a rhesus 
macaque-derived adenoviral vector (simian adenovirus 7, SAdV-7) enhances mucosal T 
cell activation within rhesus macaques. Following intramuscular SAdV-7 vaccination, we 
observed a pronounced increase in SAdV-7-specific CD4+ T cell responses in the 
peripheral blood, and more dramatically, in the rectal mucosa tissue. Vaccination also 
induced a significant increase in the frequency of activated memory CD4+ T cells in 
SAdV-7 and HAdV-5-vaccinated animals in the rectal mucosa, but not in the peripheral 
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blood. These fluctuations within the rectal mucosa were also associated with a 
pronounced decrease in the relative frequency of naïve resting CD4+ T cells.  Together 
these results indicate that peripheral vaccination with an AdV vector can increase the 
activation of mucosal CD4+ T cells, potentially providing an experimental model to 
further evaluate the role of host-vector interactions on increased HIV acquisition after 
AdV vector vaccination. 
 
Introduction  
The pursuit of an efficacious HIV-1 vaccine is an ongoing effort to minimize or 
halt the burden of this disease worldwide. Numerous T cell directed HIV vaccines have 
aimed to target immune responses that would either decrease viral load if infected or 
restrict HIV replication entirely 291,292. Notably, Merck’s Step Study was a large, phase IIb 
placebo-controlled clinical trial testing a replication-defective recombinant human 
adenovirus serotype 5 (HAdV-5) vector to deliver HIV-1 antigens gag, pol, and nef, with 
the intention of preventing HIV-1 infection by generating T cell immunity. This candidate 
HIV vaccine trial was halted in September 2007 due to statistical futility and the finding of 
a trend towards increased rates of HIV acquisition among vaccinated men with anti-
HAdV-5 seropositivity 221. Another phase IIb clinical trial using the same adenovirus 
vector is referred to as the Phambili trial, which yielded the same results of increased 
acquisition of HIV infection in some vaccinees 293. The underlying mechanism for these 
apparent increases in acquisition remains to be defined. 
During the Step trial, only peripheral blood mononuclear cells (PBMC) were 
collected, and many follow-up studies seeking to elucidate the Step outcome have 
investigated this compartment exclusively without the use of mucosal biopsy specimens 
221,222,231,234. Importantly, the gut mucosa is both the potential site of HIV transmission in 
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infected Step participants 231,234 as well as a site of AdV persistence 209. Expansion of the 
enteric virome, including mucosal adenovirus infection, has even been associated with 
pathogenic SIV infection 294. Compartmental differences in the immunological milieu 
between the blood and mucosa are well documented, and alterations in phenotype, 
functionality, activation state, or distribution of CD4+ T cells within these compartments 
may offer clues to the Step outcome. In the peripheral blood of HAdV-5 vaccine 
recipients, we found no difference in the expression of Ki67, a proliferation marker, or 
D4E7, a gut homing marker 231, in agreement with others who saw no increase in cellular 
activation 222,232. Similarly, there was no increase in D4E7 or CCR5 expression on 
peripheral blood CD4+ T cells in vaccinees during the Step Study 222,231; however in vitro 
studies suggest that HAdV-5 can induce D4E7 and CCR5 expression on expanded AdV-
specific memory CD4+ T cells 234,295, raising the possibility that HAdV-5 could have a 
specific effect in the mucosa. In these studies immune responses to adenovirus were 
evaluated using HAdV-5. It is important to note that there are currently 65 serologically 
distinct human adenoviruses and responses to adenovirus may be influenced by the 
type of adenovirus used in the study. Moreover similar studies in monkeys used human 
adenovirus to reproduce the Step trial in monkeys 188,215,219. It is important to note that 
also adenovirus can be found in macaques and that these adenoviruses are different 
from those isolated from human 208 which suggest that using a vector based on an 
endogenous rhesus macaque AdV may more accurately model host-vector interactions 
compared to an endogenous human adenoviral vector, such as HAdV-5. Vaccination 
with human AdV vector in the macaque model may produce an incomplete 
understanding of potential outcomes, as was seen with studies leading up to Step 
188,215,219.  
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To address this, we examined whether vaccination of rhesus macaques with a 
simian adenovirus SAdV-7-based vaccine vector differentially influences peripheral and 
mucosal CD4+ T cell responses and cellular activation compared to a HAdV-5 based 
vector. We find that both SAdV-7 and HAdV-5 vector vaccination can increase AdV-
specific CD4+ T cell cytokine responses in blood and, more dramatically, rectal mucosa. 
Importantly, however, both vectors heightened the cellular activation profile of total and 
AdV-specific CD4+ T cells specifically within the rectal mucosa. This increase in rectal 
mucosa CD4+ T cell activation was most pronounced after the vaccine prime, and in 
SAdV-7 vaccinated animals was accompanied by a prolonged decrease in resident 
naïve CD4+ T cells within the rectal mucosa. These data highlight the importance of 
assessing tissue-specific effects induced by vaccine platforms, and provide a potential 
mechanism by which adenovirus vaccine vectors might influence susceptibility to HIV as 
was observed in the Step study 221. 
 
Materials and Methods 
Adenovirus vectors 
Wild-type SAdV-7 was purchased from the ATCC (VR-201, originally isolated from 
rhesus monkey kidney cells). HAdV-5 was generated from a molecular clone (Clontech) 
by Vector Core (University of Pennsylvania). SAdV-7-based vectors were constructed as 
previously described 296. Briefly, the viral genome was molecularly cloned and 
expression cassettes (SARS coronavirus spike protein driven by a chicken beta-actin 
promoter, or beta-galactosidase driven by a CMV promoter) were inserted in place of an 
E1-deletion to generate replication incompetent vectors SAdV-7 SARS spike and SAdV-
7LacZ respectively. These, as well as the HAdV-5 vectors used in this study were 
propagated on HEK 293 cells and purified on CsCl gradients. 
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Animals 
17 rhesus macaques of Indian origin and captive bred were purchased from Covance 
Research Products (Alice, TX) and enrolled in this study. All animals were treated and 
cared for at the Nonhuman Primate Research Program (NPRP) facility of the Gene 
Therapy Program of the University of Pennsylvania (Philadelphia, PA) during the study. 
The study was performed according to a protocol approved by the Environmental Health 
and Radiation Safety Office, the Institutional Biosafety Committee, and the Institutional 
Animal Care and Use Committee (IACUC) of the University of Pennsylvania. All 
macaques were intramuscularly (IM) immunized 3 times with SAdV-7 or HAdV-5 at a 
dose of 1x1011 particles/injection (see Figure 2.2 for the immunization schedule). 
 
Endoscopic sampling of macaque rectum and isolation of Lamina Propria Lymphocytes 
(LPLs) All nonhuman primates (NHP) were fasted the evening before the procedure, 
with free access to water at all times. NHPs were sedated and biopsies were obtained 
utilizing an alligator-jaw style endoscopic biopsy pinch held free hand. 20 biopsies were 
taken spaced far enough apart so as not to weaken the rectal wall. Biopsies were placed 
in RPMI medium and LPLs isolated using collagenase type II as previously described 297.  
 
Blood collection and isolation of peripheral blood mononuclear cells  
PBMCs were isolated from whole blood collected in heparin-containing Vacutainer tubes 
after Ficoll (Amersham Bioscience) density-gradient centrifugation at 1000g for 25 
minutes. Cells were collected from the interphase and washed with PBS. PBMCs were 
incubated with ACK lysing buffer to lyse red blood cells, washed and resuspended in 
complete RPMI medium (Mediatech) containing 10% FBS, 2 mM glutamine, 10 mM 
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HEPES, 50 ug/ml Gentamycin sulfate and Pen/strep. 
 
AdV neutralizing antibody assay  
Anti-SAdV-7 or anti-HAdV-5 neutralizing antibody titers in serum samples were 
measured by assessing the ability of serum to inhibit transduction of the corresponding 
reporter vector, SAdV-7LacZ or HAdV-5LacZ, respectively, into HEK 293 cells. The 
reporter vector was incubated with two-fold serial dilutions (initial dilution, 1/5) of heat-
inactivated sera for 1h at 37઒°C. Serum samples were diluted with naïve mouse serum 
(Sigma Aldrich) so that the final serum concentration at all dilutions was 5઒%. 
Subsequently, the serum–vector mixture was added onto HEK 293 cells in 96-well flat-
bottomed plates (at an m.o.i. of 10 virus particles per cell) and incubated for 18–22 h. 
Cells were then washed twice in PBS and lysed, and the lysate was developed with the 
PDPPDOLDQȕ-galactosidase assay kit for bioluminescence, in accordance with the 
manufacturers' protocol (Applied Biosystems), and measured in a microplate 
luminometer (Clarity [BioTek]). The NAb titer was reported as the highest serum dilution 
WKDWLQKLELWHG$G9&09/DF=WUDQVGXFWLRQȕ-gal expression) by 50%, compared with the 
mouse serum control (Sigma S3509). 
 
Antibody reagents   
Antibodies used for surface staining included: anti-CD14 Qdot 655, anti-CD20 Qdot 655, 
anti-CD8 PE Texas Red (Invitrogen; Carlsbad, California), anti-CD28 PE-Cy7 
(eBioscience; San Diego, California), anti-CD4+ Pac Blue (Biolegend; San Diego, 
California), anti-CD25 APC-Cy7, anti-CD95 PE-Cy5, anti-HLA-DR PerCP-Cy5.5 (BD 
Pharmingen; San Diego, California). Antibodies used for intracellular staining included: 
anti-interleukin-2 (IL-2) Alexa700 (Biolegend), anti-interferon-gamma (IFNg) Alexa 700 
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(Invitrogen), anti-tumor necrosis factor-alpha (TNFa) Alexa 700, anti-CD69 APC, anti-
Ki67 FITC (BD Pharmingen). 
 
Cell processing and stimulation 
Rectal biopsies were processed within 6 hours of being collected. Rhesus macaque 
PBMC were cryopreserved in fetal bovine serum (FBS; ICS Hyclone, Logan, Utah) 
containing 10% dimethyl sulfoxide (DMSO; Fisher Scientific, Pittsburgh, Pennsylvania) 
and stored in liquid nitrogen until use. After washing fresh LPL cells or thawed PBMCs 
once in RPMI (Mediatech Inc; Manassas, Virginia), both PBMC and LPL cells were 
resuspended in complete medium [(RPMI supplemented with 10% FBS, 1% L-glutamine 
(Mediatech Inc) and 1% penicillin-streptomycin (Lonza; Walkersville, Maryland), sterile 
filtered] at a concentration of 1-2x106 cells/mL medium in FACS tubes. Cells were split 
into three stimulation conditions, at a volume of 1 mL each, with either: no stimulation, 1 
ml Staphylococcus Enterotoxin B (SEB) at a concentration of 1 mg/mL (Sigma-Aldrich; 
St. Louis, Missouri) as a positive control, or 1x1010 particles/mL of the SAdV-7 vector. 
Cells were stimulated overnight at 37qC, 5% CO2.    
 
FACS Staining Assay 
Stimulation tubes were removed from the incubator in the early morning to add 
monensin (0.7 µg/ml final concentration; BD Biosciences) and brefeldin A (1 µg/ml final 
concentration; Sigma-Aldrich; St. Louis, Missouri) and incubated for an additional 6 
hours. Cells were then washed once with PBS and stained for viability with Aqua amine-
reactive dye (Invitrogen) for 10 minutes in the dark at room temperature. A mixture of 
antibodies used for staining surface markers were added to the cells and kept at room 
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temperature for 20 minutes. Cells were washed with PBS containing 1% bovine serum 
albumin (BSA, Fisher Scientific) and 0.1% sodium azide (Fisher Scientific) and 
permeabilized for an additional 20 minutes at room temperature using the 
Cytofix/Cytoperm kit (BD Pharmingen). Next, cells were washed in Perm/Wash buffer 
(BD Pharmingen). A mixture of antibodies used for staining intracellular markers was 
added to the cells and incubated in the dark for one hour at room temperature. Cells 
were again washed with Perm/Wash buffer and fixed with PBS containing 1% 
paraformaldehyde (Sigma-Aldrich). Fixed cells were stored in the dark at 4qC until being 
collected for flow cytometric analysis. Biopsy samples from four animals at the baseline 
time point were stained with a different fluorophore panel and were not included in the 
analysis. These samples were identified in results section as “lost”. 
 
Flow Cytometric Analysis 
For each sample, between 3x105-1x106 total events were acquired on a modified flow 
cytometer (LSRII; BD Immunocytometry Systems; San Jose, CA) equipped to detect up 
to 18 fluorescent parameters. Antibody capture beads (BD Biosciences) were used to 
prepare individual compensation tubes for each antibody used in the experiment. Data 
analysis was performed using FlowJo version 9.0.1 (TreeStar, Ashland, Oregon). 
Percent expression is shown after background subtraction, where values are calculated 
as the difference between cells that were stimulated with SAdV-7 vector overnight minus 
those that were left unstimulated. AdV-specific percentages are reported as the 
population of CD4+ memory T cells which express IL-2, IFNJ, and/or TNFD within each 
compartment. While we did not include a placebo-only group, AdV-specific T cell 
responses prior to immunization at baseline should reflect this appropriately. To 
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separate naïve cells from memory, effector memory, and effector T cells, we stained with 
fluorochrome-conjugated antibodies for CD28 and CD95, where CD28+ CD95- CD4+ T 
cells indicated the naïve subset, whereas all other cells were grouped as memory. Naïve 
CD4+ T cells were gated using FlowJo for each macaque at all time points in both 
compartments. Although a CD3 antibody was not included in the panel, a CD14/CD20 
exclusion gate as well as careful gating including CD4+ bright cells, while excluding 
CD8- cells, provided assurance in the gating strategy.  
 
Figures 
Prism software, version 5.0 (Graphpad; La Jolla, California) was used to create the 
figures.  
 
Statistical Analysis  
Activation levels were summarized overall and at each time point. Graphical methods 
were employed to assess distributional assumptions of the data. SAdV-7 and HAdV-5 
group levels were modeled over time using GEEs (generalized estimating equations), 
which are a standard statistical approach for testing hypotheses involving repeated 
measures data 298. They have the advantage over traditional repeated measures 
ANOVA of being able to handle randomly missing observations from animals. GEEs 
adjust for the fact one has data from an animal over time by linking that data. They are 
similar to repeated measures ANOVA models, in that they model the inherent correlation 
from measurements made on the same animal at different times, however they can 
handle data that is missing completely at random. GEE models are flexible allowing 
overall group comparisons, comparisons at each time point, as well as within group 
comparisons to their respective baseline levels. The GEE models used were of the form: 
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f(outcome) = constant + group + time + group * time. Time was included as a categorical 
variable (rather than continuous) to allow for potentially non-linear changes from one 
time point to another. The transformation (f) used for the outcome was based on whether 
the outcome of interest was normally distributed, Poisson, or binomial (standard 
transformation for each type were used). Once the model was fitted (and assessed for 
goodness-of-fit), the average differences between groups at each time point, and also 
the differences within a group from baseline, were calculated. The p-values for these 
pair-wise comparisons were calculated using the Holm-Bonferroni method in order to 
preserve the overall Type I error rate of 0.05. This was to make sure we did not 
incorrectly find a comparison significant by chance just because of the number of 
comparisons being performed. To investigate naïve CD4+ T cells over the time course, 
four analyses were completed. Namely, the LPL outcome was evaluated separately for 
the two groups of macaques determined by the type of vaccine administered (SAdV-7 
and HAdV-5) and a similar series of analyses were conducted for PBMC in the two 
vaccine groups. For each analysis, GEE models were fit to accommodate the repeated 
measures of macaques over time. Specifically, linear GEE models were fit for each 
continuous outcome (LPL and PBMC) adjusting for a categorical ‘time’ effect and 
assuming an exchangeable correlation structure. Model-based differences of predicted 
outcomes based on each respective fitted model are presented, by vaccine type. Finally, 
raw p-values from the pair-wise differences comparing outcomes to each subsequent 
follow-up timepoint as well as comparing week 16 and week 33 have been adjusted 
using the Holm-Bonferroni method to control for multiple comparisons. 
 
Results 
Simian adenovirus type 7 immunity and vaccination  
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Adenoviral vectors are known to elicit potent T cell responses to the encoded transgenes 
and have the potential to be an important component a defense strategy against 
infectious agents such as HIV where T cell-based immunity can have an important part 
to play in either preventing infection or in containing its replication. However prior 
exposure to adenoviruses in vaccinees can result in a memory response to the payload 
adenoviral capsid antigens 207. This response is likely to be strongly influenced by the 
epitopes that are shared between capsid antigens present in the adenoviral vaccine and 
the epitopes in adenoviruses that have caused prior infections in the host. Furthermore, 
it is likely that both humans and macaques are chronically infected by adenoviruses 
203,206, resulting in ongoing restimulation of memory responses. The use of an adenovirus 
homologous to the species used in the study may be important to restimulate this 
response and properly model the immune parameters consequent on adenoviral 
vaccination, including the magnitude and the homing of the response. A phylogenetic 
analysis of monkey adenovirus hexon protein sequences (Figure 2.1) indicates that they 
are divergent from all human adenoviral species. Other macaque adenovirus proteins 
also form clusters distinct from human adenoviruses (data not shown). Thus it is 
plausible that vaccination of monkeys by a macaque-derived adenovirus such as SAdV-
7 would result in anamnestic responses that may similarly replicate what might be 
expected in human subjects vaccinated with a HAdV-5 vector. 
We vaccinated 12 rhesus macaques three times intramuscularly with 1x1011 viral 
particles (VP) of E1-deleted replication defective SAdV-7-derived vector expressing 
SARS spike (see Materials and Methods for description of construct). As a control, we 
vaccinated 5 additional rhesus macaques with an E1-delected replication defective 
HAdV-5-derived vector containing the same transgene and promoter. Ten sample 
collection time points were interspersed around the vaccinations (Figure 2.2). Prior to 
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vaccination, baseline levels of SAdV-7 neutralizing antibody (NAb) titers ranged from 
undetectable (<5) to 640, with 11/17 macaques displaying a SAdV-7 titer of d10 (Table 
2.1). All macaques had undetectable levels of HAdV-5 NAbs at baseline. Vaccination 
with either SAdV-7 or HAdV-5 vector occurred at weeks 0, 17, and 31, while rectal 
biopsies and peripheral blood were collected at -2 (baseline), 2, 5, 9, 16, 19, 21, 25, 29, 
and 33 weeks after the first immunization. Baseline rectal biopsies from four rhesus 
macaques (04C010, 05C069, 05D007, and 05D079) were lost during analysis. 
Additionally, the LPL sample from week 21 (04C058) and peripheral blood sample from 
week -2 (baseline) (04C059) were unable to be processed. Cells were stained for 
multiple markers, with a particular focus on memory markers (CD28, CD95), activation 
markers (HLA-DR, CD25, CD69, Ki67) and cytokine functionality (IL-2, IFNJ, TNFD) for 
flow cytometric analysis (representative gating shown in Figure 2.3).  
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Figure 2.1. The phylogenetic relationships between hexon proteins from human 
and monkey adenoviruses are shown. (The amino-acid sequences were aligned using 
ClustalW version 2.0.3, and refined using Gblocks version 0.91b. The alignment was 
used to construct the phylogenetic tree using PhyML version 3.0 aLRT and rendered by 
using Treedyn 198.3. Branch support values are indicated as percentages. The scale 
bar indicates the number of substitutions per site). Representatives of human 
adenoviruses from species A through G (serotypes in parentheses, and including HAdV-
5, bold font) and several monkey adenoviruses are shown. Monkey adenoviruses 
(including SAdV-7, which was used to construct vectors used in this study, highlighted in 
red) are seen to belong to a phylogenetically distinct group (grey box). 
 
 
 
 
 
 
 
Figure 2.2. Vaccination and sample collection timeline. Macaque trial design with 10 
tissue (PBMC and rLPL) collection time points, and either SAdV-7- or HAdV-5-vector 
vaccinations interspersed at weeks 0, 17 and 31. 
 
 
 
 
  
 HAdV-C 1 (0.0428)  HAdV-C 2 (0.0435)   HAdV-C 5   
   
 HAdV-B 14 (0.0389)  HAdV-B 35 (0.0384)    HAdV-B 3 (0.0220)  HAdV-B 7 (0.0186)    HAdV-E 4 (0.0757)    HAdV-D 26 (0.0432)  HAdV-D 48 (0.0415)    
 
  
HAdV-A 12 (0.0572)  HAdV-A 18 (0.0466)   
 HAdV-F 40     
 HAdV-G 52 (0.0286)  SAdV-1 (0.0378)   SAdV-7 (0.0475)    SAdV-49 (0.0474)  SAdV-50 (0.0423)    SAdV-18 (0.0543)   
  
   SAdV-20 (0.0289)  SAdV-48 (0.0278)   SAdV-3 (0.0573)   SAdV-6 (0.0625)   
 
(0.0592) 
(0.0609) 
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Table 2.1. AdV-specific humoral immune response and transgene-specific cellular 
immune response 
Macaque Sex/DOB Vaccine 
Baseline SAdV-
7 neutralizing 
Ab titera 
SARS Spike 
ELISpot: 
Baseline 
SARS Spike 
ELISpot: 
Week 2 
03C110 (M) 9/29/03 SAdV7 <5 + + 
04C068 (F) 6/9/04 SAdV7 <5 – + 
RQ6655 (M) 2/19/01 SAdV7 <5 – + 
04C010 (F) 4/14/04 SAdV7 5 – + 
04C058 (F) 5/26/04 SAdV7 5 – + 
05C041 (M) 5/23/05 SAdV7 5 – + 
04C066 (F) 6/8/04 SAdV7 10 – + 
05D007 (M) 3/7/05 SAdV7 10 – + 
RQ6529 (F) 3/20/00 SAdV7 20 – + 
03D330 (M) 8/4/03 SAdV7 40 – + 
04C078 (F) 6/15/04 SAdV7 160 – – 
05C069 (M) 6/14/05 SAdV7 640 – – 
02C015 (M) 4/17/02 HAdV5 <5 – + 
21606 (M) 5/22/00 HAdV5 <5 – + 
04C059 (F) 5/28/04 HAdV5 10 – + 
02C061 (M) 9/25/02 HAdV5 20 – + 
05D079 (M) 5/12/05 HAdV5 20 – + 
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a Reciprocal of serum dilution  
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Figure 2.3. Gating strategy for identification of CD4+ memory T cells. First, to 
ensure only live single cells were collected from either PBMCs or rectal lamina propria 
lymphocytes (rLPL), FSC-H vs FSC-A and SSC-A vs. FSC-A plots were used to exclude 
doublets and focus on singlet lymphocytes. Dead cells were excluded by gating on the 
cells negative for the viability marker Aqua Blue. Monocytes and B-cells were excluded 
via the CD14/CD20 dump gate. To select for CD4+ T cells specifically, we included the 
CD4+ and CD8- T cells. To determine memory phenotype, we used CD28 vs. CD95, 
and excluded naïve cells (CD28+/CD95-) from analysis. From here, activation markers 
(CD25, CD69, HLA-DR, and Ki67) were gated as shown on the bottom plots on 
unstimulated memory CD4+ T cells, and cytokines (IL-2, TNFD, IFNJ) were analyzed. All 
gating is shown for rectal lamina propria lymphocytes, except where indicated otherwise. 
 
 
 
 
 
 
 
Adenovirus-specific CD4+ T cells expand post-vaccination 
We first examined AdV-specific CD4+ T cells at baseline and whether AdV vector 
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vaccination influenced these frequencies. We assessed cytokine expression on memory 
CD4+ T cells after stimulation with either SEB or SAdV-7 (or unstimulated) in the rectal 
lamina propria (rLPL) and peripheral blood (PBMCs) in vaccinated macaques (Figure 
2.4). Cells from HAdV-5-vaccinated animals were stimulated with SAdV-7 to determine 
whether vaccination boosted cross-reactive responses against the heterologous SAdV-7 
vector. SAdV-7-specific CD4+ T cell responses were determined by the production of 
IFNJ, TNFD, and/or IL-2 at each collection time as shown in Figure 2.4. Several animals 
had detectable AdV-specific CD4+ T cells (response > 0.05% was considered positive) 
in both rectal lamina propria and peripheral blood at baseline, prior to AdV vector 
vaccination [4/9 SAdV-7 (3 lost to testing) rLPL, 4/12 SAdV-7 PBMC; 3/4 HAdV-5 rLPL, 
1/4 PBMC (1 lost to testing)]. Only one SAdV-7 immunized animal (04C068) had 
detectable AdV-specific CD4+ T cells within both tissues, and one HAdV-5 immunized 
animal (02C061) had AdV-specific CD4+ T cells within both tissues. We found no 
statistically significant correlation between baseline AdV-specific CD4+ T cell responses 
and pre-existing baseline SAdV-7-specific NAbs in PBMCs or rLPLs (data not shown). 
While pre-existing AdV-specific CD4+ T cells were present in both compartments, the 
magnitude of responses was consistently higher in the rectal mucosa, with 4 macaques 
exhibiting >1% expression in the rLPL (ranging from 0-1.26% SAdV-7, 0-1.5% HAdV-5), 
while 0.139% was the highest cytokine response in the PBMC (ranging from 0-0.095% 
SAdV-7, 0-.139% HAdV-5).  
After both the first and second immunization, SAdV-7-specific CD4+ T cell 
cytokine responses increased substantially in many animals and reached statistical 
significance as a group relative to baseline, within the rectal mucosa at week 5 post-
prime (P < 0.01) (Figure 2.4). We found a general association between the peak of the 
 
51 
AdV-specific CD4+ T cell response and pre-existing AdV NAb titers in the rLPL of SAdV-
7-vaccinated macaques, with the three highest responses in macaques with a NAb titer 
d 10. No association between AdV-specific CD4+ T cell response and pre-existing AdV 
NAb was found in the blood or in HAdV-5-vaccinated macaques (data not shown). The 
highest SAdV-7-specific cytokine responses were seen in the rLPL of SAdV-7-
vaccinated macaques, peaking at 14.42% (#04C058) and 16.84% (#04C066) at week 5 
post-prime, and 15.62%  (#05D007) at week 9 post-prime (Figure 2.4). An increase in 
SAdV-7-crossreactive CD4+ T cells in the rLPL of HAdV-5-vaccinated macaques was 
also noted in 3 animals with a >3% AdV-specific CD4+ T cell response at week 5 post-
prime. While increases in AdV-specific responses were also observed in PBMC, they 
were largely under 1.5%, with singular exceptions in SAdV-7-vaccinated macaques at 
isolated time points. In both SAdV-7- and HAdV-5-vaccinated macaques, rLPL that were 
stimulated with SAdV7 vector were predominantly central memory CD4+ T cells 
(CD28+CD95+), while PBMCs were a mix of naïve (CD28+CD95-) and central memory 
phenotype (data not shown). These results indicate that pre-existing AdV-specific T cell 
responses exist in both the peripheral blood and rectal mucosa, and that AdV vector 
vaccination can strongly increase AdV-specific T cell frequencies in the rectal mucosa, 
with peak mucosal responses at least 3-fold on average above that seen in peripheral 
blood. 
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Figure 2.4. AdV vector vaccination increases memory AdV-specific CD4+ T cell 
percentage. (A) A representative memory CD4+ T cell IL-2/IFNJ/TNFD response, after 
stimulation with 1x1010 pt/ml of whole SAdV-7 vector. The number in the lower right of 
the plot represents the proportion of cells that express IL-2/IFNJ/TNFD. (B) Percent 
CD4+ memory T cell IL-2/IFNJ/TNFDexpression in response to whole SAdV-7 vector 
stimulation (SAdV-7-stimulated) overnight after background (NS) subtraction. IL-2, IFNJ, 
and TNFDproduction were measured on the same fluorochrome. Peripheral blood and 
rectal lamina propria T cells from 12 SAdV-7-vaccinated and 5 HAdV-5-vaccinated 
rhesus macaques (symbols for each macaque are listed in the legend) were collected at 
ten time points including baseline (week -2) interspersed with three AdV vector 
immunizations (vertical dotted lines). Significance at any time point was calculated as a 
percent increase relative to baseline, and was determined as described in Material and 
Methods. Statistically significant increases relative to baseline are indicated above the 
red bars, (week 19 approached statistical significance). (+) Animals with no rectal biopsy 
data at baseline time point. 
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Adenovirus vector vaccination increases the frequency of activated memory CD4+ T 
cells in the rectal mucosa 
 To determine whether SAdV-7 vaccination affected the activation state of total 
CD4+ T cells in the rectal lamina propria or in blood, we assessed the expression of four 
different activation markers simultaneously (CD25, CD69, Ki67 and HLA-DR) on 
unstimulated CD4+ T cells from these sites (Figure 2.3, bottom panels). At baseline, 
rectal lamina propria lymphocytes from SAdV-7-vaccinated macaques had a slightly 
higher percentage of activated memory CD4+ T cells (range 16.8-29.5% and 11.7-19.6% 
in SAdV-7- and HAdV-5-vaccinated macaques, respectively) compared to PBMCs 
(range 7.1-20.4% and 9.8-14% in SAdV-7- and HAdV-5-vaccinated macaques, 
respectively; Figure 2.5). We found no association between baseline SAdV-7 NAb titers 
and the frequency of activated memory CD4+ T cells over the immunization period (data 
not shown). Similarly to the rLPL of unstimulated cells of SAdV-7-vaccinated macaques 
at baseline, the rLPL of SAdV-7 vector stimulated cells (Figure 2.6) from SAdV-7-
vaccinated macaques had the highest expression of activation markers on memory 
CD4+ T cells, if compared to the blood or HAdV-5-vaccinated macaques. Stimulating ex 
vivo with whole SAdV-7 vector overnight noticeably increased the percent of activated 
cells at baseline, relative to unstimulated cells. 
Following vaccination, rectal LPL CD4+ T cell activation in unstimulated cells 
increased in several macaques at week 2 (Figure 2.5). In two SAdV-7-vaccinated 
macaques (#04C010, #04C066) these levels reached nearly 50%, and SAdV-7 
vaccinated macaques averaging a 1.42-fold increase from baseline at week 2 (P < 0.01). 
These macaques maintained heightened activation for several weeks, peaking up to a 
1.5-fold group average increase from baseline at week 16. Interestingly, we also 
observed an increase in mucosal activation levels following prime and boost in some 
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HAdV-5-vaccinated animals, with one macaque (#05D079) reaching nearly 40% total 
activated CD4+ memory T cells at week 2. At week 9, HAdV-5-vaccinated macaques 
had a 1.7-fold average increase from baseline, with average values ranging between 
1.35- to 1.7-fold throughout the duration of this study. We did not find a significant 
increase of PBMC activation levels in unstimulated cells of SAdV-7- or HAdV-5-
vaccinated macaques at any study time point (Figure 2.5).  
For the SAdV-7-stimulated condition (Figure 2.6) at week 2, over 40% of the 
rLPL consisted of activated CD4+ memory T cells in 7/12 SAdV-7-vaccinated macaques 
and 2/5 HAdV-5-vaccinated macaques. Changes in mucosal SAdV-7-specific activation 
averaged consistently above 1.49-fold (SAdV-7-vaccinated) and 1.18-fold (HAdV-5-
vaccinated) during weeks 2-16. Thus, after the SAdV-7 prime, a marked increase in 
activation levels of both resting and SAdV-7-specific memory CD4+ T cells was noted in 
the rLPL, that was maintained at a heightened level relative to baseline for several 
weeks. In contrast a significant reduction in the number of activated CD4+ memory T 
cells was observed in PBMCs (Figure 2.6). These data indicate that immunization with 
an AdV vector, whether of macaque or human origin, can cause heightened activation 
marker expression in rectal lamina propria CD4+ T cells not observed in the peripheral 
blood.  
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Figure 2.5. Heightened activation marker expression on total unstimulated 
memory CD4+ T cells in rectal mucosa after AdV vector vaccination. Percent total 
unstimulated memory CD4+ T cells expressing at least one of four activation markers 
(HLA-DR, CD25, Ki67, CD69). Peripheral blood and rectal lamina propria T cells from 12 
SAdV-7-vaccinated and 5 HAdV-5-vaccinated rhesus macaques (symbols for each 
macaque are listed in the legend) were collected at ten time points including baseline 
(week -2) interspersed with three AdV vector immunizations (vertical dotted lines). 
Significance at any time point was calculated as a percent change relative to baseline 
and is shown by red lines above each plot (*p < 0.05, **p < 0.01, ***p < 0.001), and was 
determined as described in the Material and Methods section. (+) Animals with no rectal 
biopsy data at baseline time point. 
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Figure 2.6. Heightened activation marker expression on total SAdV-7-stimulated 
memory CD4+ T cells in rectal mucosa after AdV vector vaccination. Percent total 
overnight whole SAdV-7 vector-stimulated memory CD4+ T cells expressing at least one 
of four activation markers (HLA-DR, CD25, Ki67, CD69). Cells are from the same rhesus 
macaques and time points as described in Figure 5, as well as statistical significance. 
(+) Animals with no rectal biopsy data at baseline time point. 
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Increase in rectal mucosal naive CD4+ T cells after adenovirus vector vaccination 
Given the increase in both activated and cytokine-expressing memory CD4+ T cells in 
the rectal mucosa after vaccination, we examined whether there were overt changes in 
the naïve CD4+ T cell population (Figure 2.7), defined as CD28+ CD95- (Figure 2.7a), 
in the peripheral blood or rectal lamina propria following vaccination. We found a 
pronounced decrease in the relative frequency of naïve CD4+ T cells within the lamina 
propria of SAdV-7-vaccinated macaques up to week 16, after which these frequencies 
slowly returned to around baseline level by week 33 (Figure 2.7b). In contrast, the 
frequency of naïve CD4+ T cells within the PBMC of SAdV-7-vaccinated macaques 
increased steadily above baseline levels as a group average post-vaccination. At 
baseline, PBMCs had a higher naïve CD4+ T cell population ranging between 18-44.4% 
and 17.4-39.7% for SAdV-7- and HAdV-5-vaccinated macaques, respectively, while the 
rLPL varied from 1.5-24% and 1.6-9.6% for these groups. There was no evidence for an 
association between baseline SAdV-7 NAb titer and percentage of naïve CD4+ T cells 
over time (data not shown). No such overall decrease was noted in naïve rLPL CD4+ T 
cells after HAdV-5 vaccination in the control animals. 
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Figure 2.7. Naïve CD4+ T cell percentage at baseline and after AdV vector 
immunization. (A) Representative example of a flow cytometric plot gating on overnight 
SAdV-7-stimulated CD4+ T cells using memory markers CD28 and CD95, where naïve 
= CD28+, CD95-; central memory = CD28+, CD95+; effector memory = CD28-, CD95+; 
and effector = CD28-, CD95-. The number in the top right of the plot represents the 
percent of naïve CD4+ T cells. (B) Percent of naïve CD4+ T cells stimulated overnight 
with whole SAdV-7 vector. Samples were collected from macaques and immunizations 
administered as described in Figure 5. Significance at any time point was calculated as 
a percent change relative to baseline and is shown by red lines above each plot (*p < 
0.05, **p < 0.005) and was determined as described in the Material and Methods 
section. (+) Animals with no rectal biopsy data at baseline time point. 
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Discussion  
 The importance of T cell responses in HIV control is well documented 215,299,300 
and HAdV-5 vector-based vaccines have been shown to be highly immunogenic for 
inducing cell-mediated immunity 220,301. The Step and Phambili studies were able to 
generate HIV-specific T cell immunogenicity in many participants, but did not accomplish 
their goal of either preventing HIV-1 infection or lowering viral load setpoint 221, a finding 
mirrored in the recently discontinued HVTN 505 trial. Perhaps more troublingly, is the 
clear evidence of a vaccine-mediated enhancement effect for HIV acquisition reported 
from the Step and Phambili studies. The underlying mechanism for this AdV vaccine-
mediated enhancement of infection has remained controversial. It has been speculated 
that the presence of both cross-reactive AdV-specific T cells and pre-existing antibodies 
to AdV, due to previous natural exposure to any adenoviral serotype, had a direct causal 
effect on increased HIV infection, though it is unclear yet if these may be surrogates for 
a different mechanism. Other proposed theories target the inability of the HAdV-5 
vaccine to elicit a sufficiently broad immune response to counteract HIV-1 strain 
diversity, or that the AdV vector induced a response that was of an altered, undesirable 
quality 222,302.   
In this study, we used a rhesus macaque model to investigate the hypothesis that 
the rectal mucosa is a site for increased T cell activation, either global or antigen-
specific, after AdV vector vaccination. Furthermore, while we did not test it here, 
persistent adenoviral presence (17, 27) is a driver for T cell migration to the gut, possibly 
increasing the population of activated T cells for SIV to infect. Our data show that 
vaccination with AdV vector, whether of human or macaque origin, increased the 
percentage of total and AdV-specific activated CD4+ memory T cells into the rectal 
mucosa, an initial site of HIV/SIV transmission. This effect was not observed in the 
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blood. Additionally, our analyses reveal AdV vector vaccination selectively increases 
AdV-specific memory CD4+ T cell responses in the rectal mucosa above already 
existing levels. In contrast, little change in CD4+ T cell activation was found in the 
peripheral blood. We do not expect that SAdV-7-specific CD4+ T cells are any more or 
less susceptible to SIV infection compared to any other activated CD4+ T cell, but it is 
clear from our results that there is an increase in activated mucosal CD4+ T cells in 
vaccinated animals relative to baseline. Peripheral blood Ad-specific CD4+ T cells within 
these animals (n=3) did not appear to express different levels of CD4, CCR5, or MIP-1b 
upon stimulation compared to non-Ad-specific CD4+ T cells (activated or resting, data 
not shown). Future studies will be necessary to determine whether mucosal Ad-specific 
CD4+ T cells express differential levels of these markers after vaccination. Furthermore, 
our results showed that priming with SAdV-7 vector decreased the percentage of naïve 
CD4+ T cells in the rectal lamina propria, but not in blood, prior to boosting. Together, 
these findings emphasize the value of sampling from mucosal sites in the context of 
vaccination with putative HIV vaccine platforms. Indeed, mounting evidence for unique 
phenotypes between the peripheral blood and gut mucosa 303,304 indicates that analyzing 
one compartment alone is insufficient for guiding further vaccine development. 
Previous studies prior to the Step Trial had examined the impact of HAdV-5 
vector vaccination followed by SIV infection in macaques, but these models consistently 
failed to predict adverse effects of vaccination 188,215,219,305. When we compared the 
immunological effects of SAdV-7 to HAdV-5 vector vaccination, we anticipated increase 
in activated and AdV-specific CD4+ T cells specifically in SAdV-7-vector vaccinated 
macaques. Instead, we were surprised to find that HAdV-5-vector vaccinated macaques 
showed significant responses as well, suggesting a cross-reactivity of memory AdV-
specific T cell epitopes between species-specific AdV serotypes. With 65 known strains 
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of human adenovirus, and at least 25 non-human primate strains 203-206, it is likely that 
AdV-specific T cell memory and cross-reactivity may affect more rare serotypes, in 
addition to common AdV serotypes 207. We have demonstrated AdV T cell cross-
reactivity in monkeys and humans in this current study as well as previously 297, and 
recognize that changes in activation level or trafficking patterns depend on the specific 
Ad vector used, as well as the degree of cross-reactivity of the humoral and cellular 
immune responses. Furthermore, we have also shown that human intestinal tissue, 
particularly intestinal lymphocytes, can frequently be found to harbor adenoviral DNA 206 
and that captive macaques are chronically infected by adenoviruses 208. Indeed, AdV 
has been shown to persist for years in humans, and replication-defective HAdV-5 
vectors can persist over a year in mice 185,209, potentially resulting in prolonged antigen 
presentation and stimulation of T cells at a common site of entry for HIV. Notably, AdV 
vector-specific T cells have been shown to be permissive for HIV infection due to their 
high proliferative potential and expression of the HIV coreceptor CCR5 295. We did not 
measure CCR5 in this study, since most mucosal CD4+ T cells express CCR5 at 
sufficient levels to be infected by SIV, and CCR5 expression through flow cytometry may 
be below the limit of detection 273. These observations would explain how peripheral 
vaccination with an AdV-based vector may cause increased activation in the gut 
mucosa.  The combination of a complex adenoviral flora naturally found in the gut 
together with continuous AdV shedding results in persistent antigen presence acting as 
a driver for migration of cells to the gut. In addition to AdV-specific activation, global 
activation may occur as a bystander effect where the influx of AdV-specific T cells 
perturbs an existing balance leading to generalized inflammation in the intestinal 
mucosa. 
In the Step trial, when participants were divided into those who were HAdV-5 
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NAb negative (titer d18) or HAdV-5 NAb positive (titer >18) at baseline, statistically 
significant differences were seen in rates of HIV acquisition 221. Additionally, individuals 
with pre-existing HAdV-5 NAb had a lower percentage of activated AdV-specific CD4+ T 
cells in the blood 232, which may indicate AdV-specific CD4+ T cells had homed to the 
mucosa or that AdV-specific antibodies blocked AdV infection. We did not find an 
association between pre-existing SAdV-7 NAbs and increased CD4+ T cell mucosal 
activation in this study confirming early work showing no link between HAdV-5 
seropositivity and the magnitude of the Ad-specific T cell response in humans after 
infection 231, it is possible that other macaque AdV strains could be stimulating the 
immune system and influencing the expression of activation markers. AdV-directed 
cellular immune responses seen in SAdV-7 seronegative macaques likely accumulate 
from exposure to multiple AdVs 231,232 and not solely to SAdV-7. Since we have shown 
before that HAdV-5 vector vaccination in humans expands HAdV-5-specific CD8+ T cells 
306, we believe that intercurrent adenoviral infections in macaques and humans are likely 
modeling each other, as they both exhibit increases in AdV-specific T cells. Further, one 
unresolved observation was the downward trend of naïve CD4+ T cells in the rectal 
lamina propria of SAdV-7-vaccinated macaques following the vaccine prime, which 
appeared to return to baseline following the vaccine boosts. The initial decrease in naïve 
T cells may indicate trafficking of activated memory AdV-specific CD4+ T cells into the 
gut mucosa. Alternatively, our observations may reflect loss of naïve cells, expansion of 
memory cells, transition of naïve to memory, or altered trafficking of naïve cells out of the 
gut mucosa. Regardless of the underlying mechanism, the net result of this effect is a 
temporary increase in activated memory CD4+ T cells in the mucosa, creating a 
potentially favorable dynamic for increased susceptibility to HIV infection. 
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We have shown that vaccination with both an endogenous macaque, as well as a 
human, adenoviral vector can lead to significant increases in AdV-specific and activated 
CD4+ T cells in the rectal lamina propria of macaques, but not in the peripheral blood. 
While it is unclear at this time whether this induction of mucosal CD4+ T cell activation is 
sufficient to increase susceptibility to SIV infection, these results clearly suggest that 
adenovirus vaccination might indeed create such an environment. Previous adenovirus 
vaccine platform studies have not indicated an increase in SIV susceptibility, but, 
importantly, SIV challenge in these models has not taken place within the vaccine-
induced mucosal CD4+ T cell activation window that we found here. Ultimately a low-
dose SIV challenge study following AdV-based vector vaccination within the activation 
period we have found will offer a proof-of-concept for the effects of such activation. In 
the meantime, our findings raise a note of caution regarding the development of HIV 
vaccine vectors based upon mucosal pathogens, and suggest that greater consideration 
should be placed upon the induction of vector-specific immunity and more generalized 
activation effects within appropriate tissue sites. More broadly, the effects on mucosal 
CD4+ T cell activation that we have observed may not be restricted to adenovirus, and 
may be difficult to circumvent for the induction of effective mucosal immune responses 
by vaccination. 
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CHAPTER 3 
Development of a Low-Dose Intra-Rectal SIVmac251 Challenge Model After 
Adenovirus Vector Vaccination 
 
Irene Bukh, Roberto Calcedo, Mary J. Connell, Diane G. Carnathan, Martha Nason, 
Benton Lawson, Melon Tekola Nega, Thomas H. Vanderford, Jolaine M. Wilson, James 
M. Wilson, Guido Silvestri, Philip R. Johnson, Michael R. Betts 
 
Abstract 
Vaccination with the Merck human adenovirus serotype-5 (HAdV-5) vectored 
HIV-1 subtype B gag/pol/nef vaccine was unexpectedly associated with enhanced 
susceptibility to HIV-1 infection in uncircumcised HAdV-5 seropositive men by an as of 
yet unknown mechanism. It has been hypothesized that vaccination may have resulted 
in activated CD4+ T lymphocytes trafficking to mucosal sites thereby increasing targets 
for HIV infection. Recently, we found that AdV-vector vaccination in rhesus macaques 
resulted in an increase in the frequency of activated mucosal CD4+ T cells.  However, 
whether this increase in activation is sufficient to increase susceptibility to HIV/SIV 
infection is unclear. To examine this scenario, we developed a preliminary, proof-of-
concept vaccination-challenge model in order to examine vaccine-induced SIV 
susceptibility in rhesus macaques. Rhesus macaques (n=10/group) were vaccinated 
with a simian AdV-7 (SAdV-7)-vector encoding an irrelevant insert (human D-anti-trypsin) 
and challenged 5 weeks post-prime in an escalating dosing regimen starting with sub-
infectious doses (1:10,000 or 2TCID50) of SIVmac251. Although not statistically 
significant, we found a trend towards increased SIV acquisition with 5/10 SAdV-7-
vaccinated (versus 3/10 placebo-vaccinated) macaques becoming infected after 
repeated low-dose intra-rectal SIVmac251 challenge (p < 0.2). These results lay the 
groundwork for study designs to assess vaccine-induced SIV susceptibility studies in 
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rhesus macaques. Further larger-scale studies are necessary to confirm the AdV-vector 
vaccination associated trend towards increased SIV/HIV acquisition and clarify any 
associated mechanisms.  
   
Introduction 
 
Various aspects of HIV biology have complicated the pursuit of an efficacious 
vaccine. The global HIV pandemic, currently infecting an estimated 34 million people, 
continues to be a public health concern due to the lack of clear correlates of immune 
protection, viral heterogeneity, and difficulty fully eradicating viral reservoirs. In line with 
this, two main avenues for vaccine design have been pursued, including induction of 
broadly neutralizing antibodies, as well as vector-based vaccines that generate 
sustained and robust HIV-specific T cell responses 291,292. For the latter, recent large-
scale clinical trials including Merck’s Step study 221, Phambili 224, and HVTN-505 225 have 
all utilized recombinant replication-defective human adenovirus type-5 vectors (HAdV-5) 
vectors to decrease HIV viral load or prevent HIV infection altogether.  Unfortunately, all 
three trials failed to protect from HIV acquisition, and were halted 223,225. In fact, 
participants in the Step Trial revealed an enhanced susceptibility to HIV infection in 
HAdV-5 baseline seropositive, uncircumcised men 221,222.  
One hypothesis for the Step study failure was that following vaccination of 
participants with pre-existing neutralizing antibodies (nAb) to HAdV-5, expansion and/or 
activation of memory CD4+ T cells that are already present in, and traffic to, the mucosa 
307 – preferred target cells at the site of HIV transmission 61,308 – may have increased HIV 
susceptibility. However, only peripheral blood samples were collected in these clinical 
trials, obviating the ability to directly assess potential mucosal-based mechanisms 221. To 
address this experimentally, we previously examined CD4+ T cell activation and AdV-
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specific CD4+ T cell responses in the peripheral blood (PBMC) and rectal lamina propria 
(rLPL) after HAdV-5 and simian adenovirus type-7 (SAdV-7) vector vaccination using a 
rhesus macaque (RM) model.  We found that the expression of activation markers on 
CD4+ T cells was heightened in the rLPL, but not the PBMC, after both HAdV-5 and 
SAdV-7 vaccination. Further, a statistically significant increase in the percentage of AdV-
specific CD4+ T cells was found after AdV-vector vaccination in the rLPL 309. Noting 
these differences between the peripheral blood and rectal mucosa, we initiated a proof-
of-concept experiment to determine if AdV-based vector vaccination followed by SIV 
challenge during the activation window would increase SIV acquisition. Here, we 
assessed post-AdV vector vaccination induction of SIV susceptibility using an ultra-low 
dose SIV mucosal challenge. Unlike traditional vaccine studies where control animals 
are expected to become infected, we hypothesized that in order to model potential 
vaccination-induced SIV susceptibility enhancement we would need to challenge RMs 
with an extremely low dose of virus generally insufficient to infect the control animals. 
We therefore assessed susceptibility to dose-escalating intra-rectal challenges with 
SIVmac251 beginning at a minimally infectious dose (2TCID50), 5 weeks after a single 
immunization with a SAdV-7-based vector compared to a sham vaccinated control. We 
found a trend towards increased SIV acquisition with 5 SAdV-7-vaccinated versus 3 
placebo-vaccinated macaques becoming SIV+ (p < 0.2). Together, these studies 
establish a model system in which to monitor potential vaccine-induced enhancement of 
SIV susceptibility in the SIV-RM model.  
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Materials and Methods 
Adenovirus vectors 
Wild-type SAdV-7 was purchased from the ATCC (VR-201, originally isolated from 
rhesus monkey kidney cells). SAdV-7-based vectors were constructed as previously 
described 309,310. 
 
Animals 
Titration study: 15 healthy, SIV-uninfected Indian rhesus macaques (RMs) were used in 
the SIVmac251 titration study. All animals were housed that the Yerkes National Primate 
Research Center and in accordance with NIH guidelines.  These studies were approved 
the Emory University Institutional Animal Care and Use committee (IACUC).  
 
Ad-vector vaccination challenge study: Twenty captive bred five-year old male Indian 
origin rhesus macaques (Macaca mulatta) were purchased from Covance Research 
Products (Alice, TX) and enrolled in this study. All macaques were housed in 
accordance with the Guide for the Care and Use of Laboratory Animals, Public Health 
Service Policy, and Animal Welfare Act and Regulations in an AAALAC-accredited 
facility. All experiments were performed under protocols approved by The Children’s 
Hospital of Philadelphia Institutional Animal Care and Use Committee.  
 
Titration study rectal challenge with infectious simian immunodeficiency virus 
(SIVmac251)  
All 15 macaques in the titration study were challenged intra-rectally every week with a 
low-dose of SIVmac251 (provided by Dr. Nancy Miller, DAIDS, NIAID, NIH, Bethesda, 
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MD: see Supplemental Table 3.1). Challenges were performed with a 1cc slip tip 
syringe, containing 1 ml SIVmac251 inserted ~4cm gently into rectum. A plunger was 
depressed to instill virus into the rectum. The macaque was then returned to its cage in a 
prone position. Challenge doses began at 4TCID50, which were repeated for 3 weeks, 
then increased to 20TCID50. This process was repeated for 15 weeks total, increasing by 
half a log every 3 weeks, until the animal became infected. The highest dose was 
666TCID50.  Macaques became infected at various doses over the course of the study, 
with >1000 copies/ml considered infected. Animals were followed until day 42 post-
infection.  
 
AdV-vector vaccination study rectal challenge with SIVmac251 
A 3cc slip tip syringe lightly coated with lubrication jelly and containing the specific 
SIVmac251 challenge dose was gently inserted into the rectum ~4cm, and the dose was 
slowly instilled. The animal remained in prone position for at least 5 minutes after 
instillation of the virus. Animals were challenged weekly starting at week 5 post-
vaccination, repeating the same dose for 3 weeks (1x/week) and increased half a log 
every 3 weeks until the animal became infected. Challenge doses began at 1:10,000 
(2TCID50) and the highest dose was 66.6TCID50.  
 
Immunizations 
Macaques in the vaccine group received a single, intramuscular (IM) injection of SAdV-7 
at a dose of 1x1011 particles. Macaques in the placebo group similarly received a single 
IM injection of sterile saline as a control (see Figure 3.1 for the immunization schedule). 
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Endoscopic sampling of macaque rectum and isolation of Lamina Propria Lymphocytes 
(LPLs)  
All rhesus macaques were fasted the evening before the procedure, with free access to 
water at all times. NHPs were sedated and biopsies were obtained utilizing an alligator-
jaw style endoscopic biopsy pinch held free hand. 20 biopsies were taken spaced far 
enough apart so as not to weaken the rectal wall. Biopsies were placed in RPMI medium 
and LPLs isolated using collagenase type II as previously described 297. 
 
Blood collection and isolation of peripheral blood mononuclear cells  
PBMCs were isolated from whole blood collected in Vacutainer CPT cell Preparation 
Tubes with Sodium Heparin (Ref 362753, Becton, Dickinson and Company, Franklin 
Lakes, NJ) following the protocol recommended by the vendor. Briefly, tubes were 
initially centrifuged at 1700 RCF at ambient temperature to isolate the mononuclear 
cells. After centrifugation, the mononuclear cells were resuspended into the plasma by 
tube inversion and all contents above the gel were pipetted into a separate 15mL conical 
tube. PBMCs were centrifuged at 300 RCF and washed in PBS following protocol.  
 
AdV neutralizing antibody assay  
Anti-SAdV-7 neutralizing antibody titers in serum samples were measured by assessing 
the ability of serum to inhibit transduction of the corresponding reporter vector SAdV-
7LacZ into HEK 293 cells as previously described 309. The NAb titer was reported as the 
highest serum dilution that inhibited Ad9&09/DF=WUDQVGXFWLRQȕ-gal expression) by 
50%, compared with the serum control. Limit of detection of the assay is 1/5. 
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Antibody reagents   
Antibodies used for surface staining included: anti-CD14 Qdot 655, anti-CD20 Qdot 655, 
anti-CD4 PeCy5.5, anti-CD8 Qdot605 (Invitrogen; Carlsbad, California), anti-CD14 
BV650, anti-CD20 BV650 (Biolegend; San Diego, California), anti-CD28 ECD (Beckman 
Coulter; Fullerton, CA), anti-CD25 APC-Cy7, anti-CD95 PE-Cy5, anti-HLA-DR APC (BD 
Pharmingen; San Diego, California). Antibodies used for intracellular staining included: 
anti-interleukin-2 (IL-2) Alexa700 (Biolegend), anti-interferon-gamma (IFNJ) Alexa 700 
(Invitrogen), anti-tumor necrosis factor-alpha (TNFD) Alexa 700, anti-CD3 Pac Blue, anti-
CD69 PE, anti-Ki67 FITC (BD Pharmingen). 
 
Determination of plasma viral RNA (viral load) 
SIVmac251 loads were measured in plasma samples by real-time PCR as previously 
described 311. 
Cell processing and stimulation 
Rectal biopsies were processed within 6 hours of being collected. Rhesus macaque 
PBMC were cryopreserved in fetal bovine serum (FBS; ICS Hyclone, Logan, Utah) 
containing 10% dimethyl sulfoxide (DMSO; Fisher Scientific, Pittsburgh, Pennsylvania) 
and stored in liquid nitrogen until use. After washing fresh LPL cells or thawed PBMCs 
once in RPMI (Mediatech Inc; Manassas, Virginia), both PBMC and LPL cells were 
resuspended in complete medium [(RPMI supplemented with 10% FBS, 1% L-glutamine 
(Mediatech Inc) and 1% penicillin-streptomycin (Lonza; Walkersville, Maryland), sterile 
filtered] at a concentration of 1-2x106 cells/mL medium in FACS tubes. Cells were split 
into three stimulation conditions, at a volume of 1 mL each, with either: no stimulation, 1 
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Pl Staphylococcus Enterotoxin B (SEB) at a concentration of 1 mg/mL (Sigma-Aldrich; 
St. Louis, Missouri) as a positive control, or 1x1010 particles/mL of the SAdV-7 vector. 
Cells were stimulated overnight at 37qC, 5% CO2.    
 
FACS Staining Assay 
Stimulation tubes were removed from the incubator in the early morning to add 
monensin (0.7 µg/ml final concentration; BD Biosciences) and brefeldin A (1 µg/ml final 
concentration; Sigma-Aldrich; St. Louis, Missouri) and incubated for an additional 6 
hours. Cells were then washed once with PBS and stained for viability with Aqua amine-
reactive dye (Invitrogen) for 10 minutes in the dark at room temperature. A mixture of 
antibodies used for staining surface markers were added to the cells and kept at room 
temperature for 20 minutes. Cells were washed with PBS containing 1% bovine serum 
albumin (BSA, Fisher Scientific) and 0.1% sodium azide (Fisher Scientific) and 
permeabilized for an additional 20 minutes at room temperature using the 
Cytofix/Cytoperm kit (BD Pharmingen). Next, cells were washed in Perm/Wash buffer 
(BD Pharmingen). A mixture of antibodies used for staining intracellular markers was 
added to the cells and incubated in the dark for one hour at room temperature. Cells 
were again washed with Perm/Wash buffer and fixed with PBS containing 1% 
paraformaldehyde (Sigma-Aldrich). Fixed cells were stored in the dark at 4qC until 
collection. 
 
Flow Cytometric Analysis 
For each sample, between 3x105-1x106 total events were acquired on a modified flow 
cytometer (LSRII; BD Immunocytometry Systems; San Jose, CA) equipped to detect up 
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to 18 fluorescent parameters. Antibody capture beads (BD Biosciences) were used to 
prepare individual compensation tubes for each antibody used in the experiment. Data 
analysis was performed using FlowJo version 9.0.1 (TreeStar, Ashland, Oregon). 
Percent expression is shown after background subtraction, where values are calculated 
as the difference between cells that were stimulated with SAdV-7 vector overnight minus 
those that were left unstimulated. AdV-specific percentages are reported as the 
population of CD4+ memory T cells, which express IL-2, IFNJ, and/or TNFD within each 
compartment. To separate naïve cells from memory, effector memory, and effector T 
cells, we stained with fluorochrome-conjugated antibodies for CD28 and CD95, where 
CD28+ CD95- CD4+ T cells indicated the naïve subset, whereas all other cells were 
grouped as memory. Naïve CD4+ T cells were gated using FlowJo for each macaque at 
all time points in both compartments.  
 
Figures 
Prism software, version 5.0 (Graphpad; La Jolla, California) was used to create the 
figures.  
 
Statistical Analysis  
This study was designed to have sufficient power (80%) to detect a significant result 
(p<0.05) with group differences in SIV acquisition if 0/10 placebo group and 5/10 vaccine 
group RM became infected, or 1/10 placebo group and 7/10 vaccine group RM became 
infected. The groups were compared with respect to the probability of infection as a 
function of challenge dose using a logistic regression model. In order to account for the 
structure of the data, p-values were computed based on a permutation null distribution. 
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The permutation null distribution was created by randomly permuting the group labels 
between animals 1000 times and recomputing the statistic after each permutation; the 
observed statistic was then compared to this permutation null distribution. 
 
Results 
SIVmac251 low-dose titration 
 We recently described the development and use of the simian adenovirus type 7 
(SAdV-7) vector in order to model natural adenovirus immunological responses in 
macaques compared to using a human AdV vector 309,310. In order to assess whether the 
vaccine-induced mucosal CD4+ T cell activation we observed previously induced a 
heightened state of SIV infection susceptibility, we first needed to develop an ultra-low 
dose challenge system. Therefore, we first performed a low-dose intra-rectal titration of 
our SIVmac251 stock in 15 RM. We began this titration at a 1:5000 (4TCID50) dilution 
that, in previous titration studies involving only a few macaques, appeared to produce 
little or no SIV infection. Two of fifteen macaques were infected at the lowest 1:5000 
dose (Supplemental Table 3.1). As a result, we started our vaccination-challenge study 
at 1:10,000 (2TCID50), in order minimize the chance of infection in the control group.  
 
Simian adenovirus type 7 immunization/challenge study design 
Twenty Indian-origin rhesus macaques were stratified into vaccine and placebo groups 
based on group distribution of baseline cytokine and activation marker expression, as 
well as baseline SAdV-7 neutralizing antibody (nAb) titers (Supplemental Table 3.2). 
SAdV-7 nAb titers ranged from <5 (undetectable) to 640 in one macaque, and did not 
correlate with SIV acquisition by the end of the study. We vaccinated 10 RM 
intramuscularly with 1x1011 viral particles (VP) of an E1-deleted replication-defective 
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SAdV-7 vector diluted in sterile saline (see Materials and Methods for construct 
description). As a control, we vaccinated 10 RM with sterile saline. Peripheral blood 
mononuclear cells (PBMCs) and rectal lamina propria T lymphocytes (rLPL) were 
obtained at two baseline time points (week -5 and week -3) and week 2 post-vaccination 
(Figure 3.1). Once rectal pinch biopsies were collected at week 2 post-vaccination, 
macaques were rested three weeks to allow healing of the rectal mucosa tissue before 
challenge. Based on our previous study, AdV-induced rLPL CD4+ T cell activation peaks 
at 5 weeks and decreases nearly to baseline by 16 weeks post-SAdV-7 vaccination. For 
this reason, we chose to structure the timeline such that the peak window of activation 
could overlap with the SIV challenge window. This would help determine if increased 
CD4+ T cell activation in the rectal mucosa due to SAdV-7 vector vaccination may 
increase the likelihood of SIV acquisition. Starting at week 5, macaques were intra-
rectally challenged weekly with SIVmac251, starting at a 1:10,000 (2TCID50) dose 
dilution. Macaques were challenged 3x/dose before increasing the dilution half a log, 
until SIV acquisition, as indicated by weekly plasma viral load assays. SIV challenges 
continued until week 16 (1:300 or 66.6TCID50), at which point 12 macaques total did not 
acquire SIV. Macaques were monitored for viral set-point once infected.   
 
 
 
 
Figure 3.1. Study timeline. Overview of the three peripheral blood mononuclear cell 
(PBMC) and rectal lamina propria T lymphocyte (rLPL) collection time points 
interspersed around vaccination (day 0). Intra-rectal SIV challenges began at week 5 
post-vaccination (post-vx) and continued until week 16.      
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Supplemental Table 3.1. SIVmac251 low-dose intra-rectal titration. 15 rhesus 
macaques were SIV challenged intra-rectally weekly and viral loads were monitored 
weekly until SIV acquisition. Challenge doses began at 1:5000 (4TCID50) and was 
repeated 3 times before increasing by half a log every three weeks, until SIV infection 
occurred. All 15 macaques became SIV+ by the 14th challenge at 1:30 dilution.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3.1. Representative flow cytometry gating. Rectal LPL and 
PBMCs were gated on single cells, including live lymphocytes and excluding CD14/20 
cells. Within the CD3+ pool, CD4+/CD8- T cells further excluded naïve (CD28+/CD95-) T 
cells. Plots on the top two rows were obtained from the rLPL at baseline week -5. The 
four bottom panels represent activation marker expression in the rLPL (left) and PBMC 
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(right).     
 
Supplemental Table 3.2. SAdV-7 baseline neutralizing antibody (nAb) titers. Titers 
are reported for placebo-vaccinated and SAdV-7-vaccinated macaques, the assay is 
described in the Materials & Methods. (*) indicates that macaque acquired SIV before 
the study completion.     
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Immunologic assessment of SAdV-7 vectored vaccine induced responses 
Previously, we found that SAdV-7 vector vaccination preferentially induced 
strong AdV-specific T cell responses, heightened CD4+ T cell activation, and decreased 
the frequency of naïve CD4+ T cells in the rectal lamina propria of vaccinated RM (37).  
As such, we first sought to confirm that the SAdV-7 vector used here similarly induced 
these changes within the rectal lamina propria following immunization.   
Baseline AdV-specific CD4+ T cells were detectable for all macaques in at least 
one compartment (Figure 3.2; representative data shown in Supplemental Figure 3.1), 
with 7/10 SAdV-7-vaccinated RMs and 9/10 placebo-vaccinated RMs showing 
responses in the peripheral blood, and 10/10 SAdV-7-vaccinated RMs and 9/10 placebo-
vaccinated RMs showing responses in the rectal mucosa (response >0.05% was 
considered positive). However, while SAdV-7 vaccination resulted in a greater average 
percentage of AdV-specific CD4+ T cells in both PBMC (0.55%) and rLPL (0.28%) at 
week 2 relative to placebo vaccination (PBMC 0.09%, rLPL 0.16%), this increase was 
not statistically significant.  
 We next assessed CD4+ T cell activation at baseline weeks -5 and -3, and week 
2 post-vaccination (Figure 3.3) to determine whether vaccination with this SAdV-7 
vector induced heightened mucosal CD4+ T cell activation. However, unlike our previous 
study, we found no significant changes in the percent of total activated CD4+ memory T 
cells (representing the summed percentages of any CD4+ memory T cell that expresses 
at least one (or more) of the four activation markers) before and after vaccination. As 
expected, the rectal lamina propria had, on average, consistently higher expression of 
activation markers compared to PBMCs (rLPL ~35% vs. PBMC ~16%). Moreover, the 
percent total CD4+ T cell activation marker expression was comparable between the 
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placebo and vaccine groups within each compartment at both baseline and week 2 post-
vaccination.  
Finally, we measured naïve CD4+ T cells (Figure 3.4), defined as CD28+ CD95-, 
in the peripheral blood and rectal lamina propria for cells stimulated with SAdV-7 
overnight at all three time points. As expected, the average relative percentage of naïve 
CD4+ T cells was much higher in PBMCs (baseline placebo 45.62% vs. baseline SAdV-
7-vaccinated 48.18%) (week 2 placebo 46.7% vs. week 2 SAdV-7-vaccinated 42.09%)  
than the rLPL (baseline placebo 7.15% vs. baseline SAdV-7-vaccinated 5.11%) (week 2 
placebo 8.69% vs. week 2 SAdV-7-vaccinated 10%). Overall, the values did not fluctuate 
significantly before and after vaccination in any group, except for SAdV-7-vaccinated RM 
#08C014 displaying an unusually high naïve CD4+ T cell percentage at week 2 post-
vaccination.  Taken together, these results indicate that the SAdV-7 vector used in this 
study performed quite differently in this group of RM compared to that used in our 
previous study. 
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Figure 3.2. CD4+ memory AdV-specific T cell cytokine responses in the PBMC and 
rLPL. Cytokine responses (IL-2, IFNJ, TNFD) were combined for SAdV-7 overnight-
stimulated CD4+ memory T cells and baseline subtracted from unstimulated cells. 
Values are shown for both baseline time points (weeks -5 and -3) and week 2 post-
vaccination. Boxes around macaque numbers in the legend on the left indicate that 
animal became SIV+ before study completion. 
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Figure 3.3. Percent of total activated CD4+ memory T cells with no overnight 
stimulation. Values are shown for both baseline time points (weeks -5 and -3) and week 
2 post-vaccination in the peripheral blood (PBMC) and rectal lamina propria. Activation 
values for each macaque represent the summed percentages of any CD4+ memory T 
cell that expresses at least one (or more) of the four activation markers measured in this 
study (HLA-DR, CD25, CD69 and/or Ki67) within that time point. Boxes around macaque 
numbers in the legend on the left indicate that animal became SIV+ before study 
completion.   
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Figure 3.4. Percent of naïve CD4+ T cells at each time point. Naïve cells are 
CD28+/CD95- by flow cytometry (a representative plot can be found in Supp. Fig. 1). All 
cells were SAdV-7-stimulated overnight before fluorochrome staining. Values are shown 
for both baseline time points (weeks -5 and -3) and week 2 post-vaccination in the 
peripheral blood (PBMC) and rectal lamina propria. Boxes around macaque numbers in 
the legend on the left indicate that animal became SIV+ before study completion.  
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Increased trend of SIV acquisition after SAdV-7 vector vaccination relative to placebo 
 Starting at week 5 after either SAdV-7 vector or placebo vaccination, we began 
weekly intra-rectal low-dose SIV challenges at 1:10,000 (2TCID50) for all 20 macaques 
(Supplemental Table 3.3). Although we did not see evidence of increased AdV-specific 
or activated CD4+ T cells at week 2 post-vaccination, the week 5 challenge time point 
was chosen based on the peak activation levels observed in our previous study, which 
peaked at week 5 and subsided through week 16 (37). As shown in Figure 3.5, 5 SAdV-
7-vaccinated RMs and 3 placebo-vaccinated RMs became infected throughout the 
challenge course.  The time of SIV acquisition did not occur with any preference towards 
vaccination group. While this value is not statistically significant between groups, it 
trends towards significance (p < 0.2). Peak viral loads for SAdV-7-vaccinated macaques 
ranged from 9.34x105 (#08C026) – 9.53x106 (#08C008) copies/mL and in placebo-
vaccinated macaques ranged from 1.45x104 (#08C045) – 2.96x107 (#07D228) 
copies/mL. Although macaques were not always followed through to final viral load set-
point, final viral loads prior to euthanasia were not consistently higher or lower for either 
vaccination group (range of set-points for SAdV-7-vaccinated RMs was 3.57x102 
(#08C026) – 2.24x105 (#08C008) and for placebo-vaccinated RMs was 1.3x102 
(#08C045) – 1.49x105 (#08C015)). Finally, we found no association between pre-
challenge activation levels, AdV-specific CD4+ T cell frequency, or pre-vaccination AdV 
titers (data not shown) and infection status or infection rate within either the vaccine or 
placebo groups.  
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Figure 3.5. Viral loads in SIV-infected macaques after dose-escalating intra-rectal 
challenges. Three placebo-vaccinated macaques (gray dotted lines) and five SAdV-7-
vaccinated macaques (black solid lines) acquired SIV as a result of weekly SIV 
challenges (p < 0.2). Challenge doses were administered 3x/dose before increasing to 
the next dose to all 20 macaques. SIV challenges began at 5 weeks post-vaccination 
and continued until 16 weeks post-vaccination.      
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Supplemental Table 3.3. SIV viral loads in rhesus macaques (RMs). Numerical 
presentation of data shown in Figure 5. Three placebo-vaccinated RMs and five SAdV-7-
vaccinated RMs became SIV+ and were sacrificed when viral loads started to reach set-
point. Dose causing infection is administered 1 week prior to first detectable viral load. 
Undet = undetectable, assay sensitivity is 60 copies/mL.      
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Discussion 
 Numerous follow-up studies have aimed to understand the mechanisms of 
HAdV-5-based vector vaccination clinical trial failures, without any definitive answer.  
Some of these studies have attempted to elucidate the outcome of the Step Trial through 
examination of the peripheral blood only 231,232,306, leading to subsequent reports citing 
the value of both peripheral blood and gastrointestinal mucosa analyses. Our study was 
designed to clarify if increased frequencies of AdV-specific CD4+ T cells and CD4+ T 
cell activation levels in the gut mucosa after AdV-based vector vaccination that were 
evident in our previous study would lead to increased SIV susceptibility after challenge. 
We saw a trend of increased SIV acquisition after intra-rectal low-dose challenges in 
SAdV-7-vaccinated macaques (5/10) compared to placebo-vaccinated macaques (3/10) 
(p < 0.2), but we cannot at this time attribute this trend to mucosal CD4+ T cell activation 
or AdV-specific T cell responses. With a small sample size of ten macaques per group, 
and only one post-vaccination sample collection time point, we believe that additional 
exploration is necessary to determine whether AdV vectored vaccination results in 
increased SIV infection susceptibility.  
The clear effects of AdV vectored vaccination we were able to show in our 
previous study, which displayed significant increases after vaccination relative to 
baseline in both AdV-specific CD4+ T cells and activated CD4+ T cells in the rectal 
mucosa, were not evident in our results here. Although we did verify that all the SAdV-7 
vector vaccinated macaques (except #08C006) did seroconvert by week 2 post-
vaccination (data not shown), macaques, like humans, show substantial variation, and 
this can be seen in immunological responses. One caveat of this study is that the 
genetic diversity (including MHC class I alleles, TRIM5D) can make smaller studies, such 
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as these, difficult to perform. Additionally, these animals came from a different source 
and with different housing conditions than our previous study, both of which may be a 
factor in the baseline and post-vaccination responses. We saw higher baseline levels of 
AdV-specific CD4+ memory T cell responses, albeit insignificantly, than previously. Also, 
at week 2 post-vaccination, none of the macaques had AdV-specific CD4+ T cell 
responses above ~2%, whereas in our previous study, 5 macaques had elevated AdV-
specific CD4+ T cell responses in the rLPL. AdV-specific CD4+ memory T cells reached 
statistically significant increases only starting at week 5 post-vaccination in our last 
study, so it is possible that if we were able to wait longer to assess these responses, we 
may have seen changes here as well. Further, the percent of total activated CD4+ 
memory T cells at baseline in the rectal mucosa was substantially higher in the current 
study (~15-60% vs. ~10-30% previously), although levels of activation in the peripheral 
blood were similar. It is unclear what the cause of this large difference is, but it is 
possible that macaques in this study were exposed to more antigens at baseline or had 
a substantially different gut microbiome leading to differential antigen-induced CD4+ T 
cell activation. A larger study may have been able to produce a statistically significance 
outcome, rather than a trend towards SIV acquisition, as it would have balanced out 
genotypes and immune responses.   
There are a few main factors that influenced the design of this study and are 
important to consider with regards to the data. The primary focus of our study design 
was to synchronize the SIV challenges with the peak of SAdV-7 vector vaccination-
induced mucosal CD4+ T cell activation, which (from our first study) occurred at 
approximately 2-5 weeks post-vaccination, and gradually subsided by week 16. We 
hypothesized that exposure to SIV during this time period would lead to increased SIV 
acquisition in the SAdV-7 vector vaccinated group relative to the placebo group. As 
 
87 
such, we were only able to obtain a single post-vaccination week 2 rectal biopsy to 
assess vaccine-induced effects in order to provide a long enough time for the rectal 
mucosa to heal prior to SIV challenge at week 5. Based on our data before where 
several macaques showed peaks of activation after week 2 309, we recognized that 
immunological dynamics might be slightly different in this group of macaques and we 
could miss sampling the rectal mucosa activation peak. Finally, we were limited by 
relatively small groups (20 macaques split evenly into vaccine and placebo recipients), 
which limited our statistical power. While we saw a trend towards increased SIV 
acquisition in the SAdV-7 vector vaccinated group, this was unfortunately not enough to 
reach statistical significance. The conclusion from the Step Study that the Merck HAdV-5 
HIV-1 subtype B gag/pol/nef vaccine may have increased HIV acquisition was based on 
49/914 male vaccine recipients versus 33/922 male placebo recipients acquiring HIV 221. 
Therefore, this is a difference of 16 infections in 1,836 men (0.87%) between vaccine 
and placebo groups – a relatively marginal increase in HIV acquisition, but significant 
due to the large size of the study population.  
Unifying the HIV vaccine community towards an appropriate non-human primate 
model to illustrate immunological and virological outcomes from clinical efficacy trials 
using AdV-based vectors and other vector-based HIV vaccines will be critically important 
as the field progresses forward. The failure of the Step Trial, Phambili, and HVTN-505 
were disappointing, but were fairly consistent with previous SIV vaccine studies using 
HAdV-5 vectors 188,215,216. Although the mechanism for the failure of the Step Study has 
yet to (and may never) be resolved, the developmental path of any HIV vaccine should 
thoughtfully employ the NHP model in such a way to directly assess potential vaccine 
enhancement effects at relevant challenge sites. The studies we have described here 
provide an initial strategy upon which future studies can build to improve our ability to 
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properly assess potential detrimental effects of suboptimal HIV vaccine strategies.   
CHAPTER 4 
Discussion 
Significance 
Although HIV was found to be the causative agent of AIDS over 25 years ago, 
there is still no effective cure. There have been numerous vaccine trials, but HIV 
treatment still relies on a combination of three or more medications (to decrease the 
likelihood of HIV developing resistance) called highly active antiretroviral therapy 
(HAART). There are several classes of drugs that target different stages of the HIV life 
cycle via inhibition of HIV enzymes, leading to suppressed viral burden and thus 
improved morbidity and mortality. HAART consists of a “cocktail” of medicines that 
include nucleoside/nucleotide and non-nucleoside reverse transcriptase inhibitors, 
protease inhibitors, entry inhibitors, and integrase inhibitors. Although HAART has 
allowed HIV-infected individuals to live decades more than before the advent of these 
drugs, there are still difficulties with high cost, availability, side effects, drug adherence 
and the potential for drug-resistant viruses. For these reasons, research has continued 
to search for a vaccine that affords reliable protection and/or is able to eliminate HIV 
from infected individuals.   
Strategies for a vaccine have ranged from the classically empirical, such as the 
first HIV vaccine candidate in 1987, to increasingly refined approaches utilizing structural 
biology and virally vectored vaccines. Nearly 100 clinical vaccine trials have taken place, 
many of them first tested in a NHP model and challenged with SIV or SHIV (chimeric 
SIV/HIV). Vaccination and subsequent challenge of NHPs has aimed to elucidate the 
immunogenicity and efficacy of vaccines with the goal of inducing either T cells or 
antibodies, or both. The NHP challenge model is continuously undergoing evolution and 
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refinement, in order to more effectively simulate the outcome in humans. What started 
as a field that challenged NHPs with large doses of cloned viruses, is now more 
appropriately also using lower-dose, swarm-based mucosal challenges – closer to 
reflecting human exposure during transmission. Nonetheless, the “ideal” HIV model is 
still disputed, and it is possible that this debate will continue until clear correlates of 
protection for HIV emerge.  
There are several benefits of the NHP model over other small-animal models for 
studying HIV. SIV/SHIV infection in macaques closely resembles HIV in humans based 
on the likeness in: susceptible cell types to infection, depletion of CD4+ T cells with a 
particularly rapid decline in the gastrointestinal mucosa, and the progression to AIDS 
109,312. Anatomically and physiologically, macaques and humans are similar, most 
importantly at the sites of SIV/HIV infection and dissemination. Furthermore, due the 
close phylogeny, many of the genes that control HIV immune responses are either 
directly orthologous or, often, at least very similar [reviewed in 104]. For these reasons, 
using an NHP model to test HIV vaccines offers an opportunity to reveal, with a fair 
degree of predictable accuracy, whether the vaccines will succeed.  
In this dissertation, our goal was to understand the virological and immunological 
mechanisms that led to the failure of the Step Trial using a rhesus macaque model. We 
hypothesized that immunizing macaques with a species-specific SAdV-7 vectored 
vaccine would lead to reactivation of cross-reactive T cell responses, as well as nAb 
responses in RMs that had been previously exposed to SAdV-7. AdV-specific CD4+ 
memory T cells already present in the gut mucosa are activated, as well as activation of 
AdV-specific CD4+ T cells in the peripheral blood which traffic to the original mucosal 
site of infection (due to AdV fecal-oral route of transmission). The establishment of 
increased activated CD4+ T cells in the mucosa, the preferred targets of SIV, resulting 
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from AdV-vectored vaccination would create a favorable dynamic for a greater likelihood 
of SIV acquisition.  We vaccinated using both a human (HAdV-5) and simian (SAdV-7) 
adenovirus-based vector, intra-rectally challenged macaques with low doses of the 
swarm-based SIVmac251 virus, and obtained peripheral blood mononuclear cells and 
rectal lamina propria T lymphocytes. We believe that the combination of methods we 
have employed is as close to “ideal” as we are able to come, currently, in the NHP 
model to understand the Step Study and other virally vectored HIV vaccines. I argue that 
when investigating a mucosally transmitted viral vector, such as adenovirus, in 
combination with a mucosally transmitted pathogen, such as HIV, analysis of samples 
from mucosal, as well as peripheral blood, compartments are critical to predict and 
understand the vaccine’s mechanisms of action. Our successful development of a 
system to model AdV vectored vaccination followed by low-dose intra-rectal challenge, 
which trends towards CD4+ T cell activation-induced SIV acquisition in rhesus 
macaques, can be further modified and improved upon in future studies.   
 
Understanding the consequences of mucosal CD4+ T cell activation after AdV 
vectored vaccination 
 After the Step Trial revealed an enhanced susceptibility to HIV infection in HAdV-
5 vector vaccinated individuals that were uncircumcised and HAdV-5 seropositive at 
baseline 221, studies began to investigate the mechanism for this unfortunate outcome.  
Post-hoc analyses focused on examination of peripheral blood from Step Study 
participants, leading to results that, while valid based on PBMC analyses, were not 
necessarily indicative of gastrointestinal mucosal cell phenotype and functionality. 
Previous work by Hutnick et al. from our lab has investigated PBMC samples from the 
Step Study. It was shown that following HAdV-5 vector vaccination, both CD4+ and 
 
91 
CD8+ AdV-specific T cells from PBMCs transiently expand, but there was no durable 
change in polyfunctionality, phenotype or homing marker expression 306. Subjects who 
were either HAdV-5 seropositive or seronegative at baseline, prior to HAdV-5 vector 
immunization, had similar baseline and post-vaccination HAdV-5-specific CD4+ T cell 
responses 231. This suggested, from peripheral blood analyses, that HAdV-5-specific 
CD4+ T cells did not lead to the increased HIV susceptibility seen in HAdV-5 baseline 
seropositive Step Trial participants. These findings are valuable, but the work presented 
in this dissertation further delves into CD4+ T cell phenotypes in the rectal mucosa – the 
site of HIV infection and dissemination in the Step Study.   
 It was not possible to obtain rectal biopsies from the Step Trial, since they were 
not collected 221; therefore using the macaque model to replicate the AdV-based vector 
prime-boost-boost regimen was the best alternative. The main concern to address was 
the presence of pre-existing HAdV-5 neutralizing antibodies (from baseline seropositive 
individuals), which can limit vaccine efficacy by targeting and eliminating the AdV vector 
as well as transgene products 313. Approximately half of the adult US population is 
HAdV-5 seropositive, yet outside of the US, >90% of individuals have pre-existing nAb 
247. In order to successfully model the Step Study in rhesus macaques and determine if 
pre-existing nAb responses were a factor in the outcome, we developed a vector using 
macaque-specific simian adenovirus type 7 (SAdV-7) for immunization 310. Since nAb 
are serotype-specific, we believed it was appropriate to use a macaque-specific AdV-
based vector in a macaque analogously to the way that a human-specific AdV-based 
vector was used in humans in the Step Trial.  
After baseline PBMC and rLPL samples were collected, we challenged 
macaques with either SAdV-7 or HAdV-5 three times (day 0, week 17, week 31), and 
obtained samples at ten time points throughout the immunization period. Examination of 
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total CD4+ T memory cell activation (based on CD25, CD69, HLA-DR and Ki67) in the 
rLPL revealed statistically significant increases in both HAdV-5 and SAdV-7 vector 
vaccinated macaques, and AdV-specific CD4+ memory T cell percentage in the rLPL 
was statistically increased in SAdV-7 vector vaccinated macaques. This implied that 
using seroprevalence to determine the presence of T cell responses was not 
appropriate. Previous studies have shown that AdV-specific T cells are cross-reactive 
202,314, even in subjects that have never been exposed to the vector serotype used for 
immunization. AdV-specific CD4+ memory T cells can either traffic from the blood to the 
mucosa, or cells already present in the mucosa can become reactivated 203,234. We also 
did not find a correlation between baseline SAdV-7 nAb responses with any of the CD4+ 
T memory phenotypes we were investigating (as expected, HAdV-5 nAb responses were 
uniformly not present). Taken together, these results indicated that AdV-based vector 
vaccination, whether using SAdV-7 or HAdV-5 vector, increased the percent of AdV-
specific and activated CD4+ memory T cells in the rectal mucosa, but not in the blood, 
and can thus establish a scenario of an increased risk of SIV/HIV acquisition due to the 
greater availability of target cells at the site of infection. We used this outcome to move 
forward with a proof-of-concept SIVmac251 intra-rectal low-dose challenge study after 
SAdV-7-based vector vaccination.    
 Our AdV-based vector vaccination followed by SIVmac251 challenge study was 
only designed to investigate the effects of SAdV-7 as a vector. We believe, though, that 
the AdV-specific T cell cross-reactivity previously seen with HAdV-5 vector vaccination in 
macaques may imply that these results will translate to rare vectors that are in 
development as well. Our goal was to first titrate SIVmac251 to a sufficiently low-dose 
such that any SIV acquisition that occurred after SAdV-7-based vector vaccination could 
be attributed to rectal mucosal CD4+ memory T cell activation-induced susceptibility. 
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This titration study was unique in that it rigorously tested 15 macaques with an intra-
rectal low-dose SIV to determine activation-induced SIV susceptibility. We are unaware 
of any previous studies that have demonstrated low-dose SIVmac251 infection with such 
a dependable quantity of animals upon which to base future challenge experiments. 
Unfortunately, in the challenge study that followed, after we collected PBMC and rLPL at 
baseline and week 2 post-vaccination, neither the vaccine or placebo groups showed 
evidence of a significant change in AdV-specific CD4+ memory T cells or CD4+ memory 
T cell activation in the peripheral blood or rectal mucosa. We did show evidence for a 
trend towards SIV acquisition in the SAdV-7-based vector vaccine group, and recognize 
that the small size of the study was a limiting factor. Another obstacle was weighing the 
cost of obtaining a single week 2 post-vaccination rectal biopsy sample versus the 
benefit of initiating weekly SIV intra-rectal challenges earlier within the predicted window 
of increased CD4+ memory T cell activation in the rLPL. It is certainly possible that with 
an increased number of RMs, a similarly designed study may be able to reach statistical 
significance, although determining a more optimal SIV challenge and rLPL sample 
collection timeline may be worth investigating.  
As I previously alluded to in this thesis, macaques are not without faults and the 
outcome of studies are not always foreseeable. There is substantial variation between 
macaques, as there are in humans, and this variation can be seen in SIV infection. This 
is a positive attribute in the sense that the differences seen in humans worldwide will be 
modeled in RM experiments, but the genetic diversity (including MHC class I alleles) can 
make smaller studies difficult to perform. The MHC genes in RMs are highly polymorphic 
and encode molecules that present virus-derived peptides on the surface of infected 
cells for T cell recognition. These MHC polymorphisms can profoundly influence the 
ability of the immune system to control SIV, since some MHC class I alleles are 
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associated with containment of viral replication 212,315,316. This is one caveat of our SIV 
challenge study, which had one vaccine and one placebo group of 10 macaques each. 
These RMs were not evaluated for the presence of protective MHC class I alleles 
between placebo and control groups, and thus the protective effects of these alleles may 
have been overrepresented in one of the groups and could confound our interpretation. 
Additionally, these animals came from a different source and were housed in a different 
facility than our first SAdV-7-based vector vaccination study. Thus, the differences that 
we saw in CD4+ T cell activation status and AdV-specific CD4+ T cell responses 
between our two studies could be a consequence of this animal-to-animal variation. A 
larger study may have been able to produce a statistically significance outcome, rather 
than a trend towards SIV acquisition, as it would have balanced out genotypes and 
immune responses.   
Concurrent with our the ongoing search for a mechanism to explain the failure of 
the Step Study, AdV-based vector vaccines for HIV are still continuing to be developed. 
AdV-specific T cell cross-reactivity is important to consider as the field of AdV vaccines 
moves forward with pre-clinical and Phase I trials using vectors based on rare AdV 
serotypes with low seroprevalence. Our lab has shown that AdV-reactive T cells have an 
effector and effector memory-like phenotype, indicating that these CTLs produce 
functions that make them particularly efficient at eliminating vector-infected cells 202.   
The limitations of pre-existing nAb should hypothetically be avoided in rare AdV 
serotypes, but cross-reactive AdV-specific CD8+ T cells will still likely hinder transgene 
and vector responses. Furthermore, using heterologous AdV serotypes during a series 
of vaccinations will similarly be susceptible to targeting by cross-reactive AdV-specific 
CD8+ T cells.  
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Future directions 
A few years after HIV was confirmed as the cause of AIDS, the US Health and 
Human Services Secretary promised an HIV vaccine within two years, based on recent 
successes in the vaccine field at the time. Unfortunately, HIV’s rapid ability to escape 
from neutralizing antibodies, establishment of a latent viral reservoir, and other biological 
aspects of HIV, have illustrated that the traditional vaccine approach will not be 
sufficient. Starting from the first Phase I HIV vaccine trial in 1987 using a gp160 subunit 
vaccine to the most recent halting of HVTN 505, due to a lack of efficacy 225, many HIV 
trials have failed (these are more thoroughly reviewed in the Introduction). Throughout 
these past 25 years, though, NHP models have been used as the basis for preliminary 
results and largely with predictable efficacy. What have we learned from these clinical 
trials? First, a vaccine should optimally combine a strong induced T cell response, 
together with breadth, activation, and sufficient duration. Ideally, T and B cell responses 
should each effectively target vulnerable parts of HIV previously shown to be useful (i.e. 
CD8+ T cells specific to Gag p24 rather than towards Env). Also, for HVTN 505, the 
difference in HIV acquisition between vaccine and control groups was not significant 225. 
This may indicate that when removing the risk factors seen in the Step Study 
(seropositive HAdV-5 baseline status and uncircumcised individuals), there might still be 
a chance that the strong immune responses AdV vectors induce may be beneficial when 
using rare AdV serotypes. Of note, the SIVmac251 challenge model tested in NHPs prior 
to HVTN 505 predicted a failure to prevent SIV acquisition and any control was modest 
and short-lived 317-319. Finally, HAdV-5 vectored vaccines were not originally designed to 
induce virus-neutralizing antibodies. Induction of broadly-neutralizing antibodies is a 
difficult task, but may be a direction future vaccine trials can aim for in combination with 
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effective T cell responses.  
Of the six large-scale HIV-1 vaccine trials, RV144 was the only one to show 
decreased transmission in the vaccine relative to the placebo group, with a modified 
intent to treat (mITT) efficacy of 31%. What was it about this vaccine trial compared to 
the others that led to this protection and what can we learn going forward in future HIV-1 
vaccine studies? First, there were two humoral immune measurements that correlated 
with HIV-1 infection risk. IgG antibodies to the V1/V2 region of HIV-1 gp120 correlated 
with a decreased HIV-1 infection risk, and plasma HIV-1 Env-specific IgA score 
correlated with an increased risk of infection in the vaccine arm. Further studies also 
indicated that the vaccine-induced immune response in RV144 may have been due to 
the breadth of the V1/V2-specific response, as it cross-reacted to multiple HIV-1 clades. 
Also, within the factors that correlated with HIV infection risk were other humoral 
responses and host genetics (including both HLA Class I and II alleles), indicating that 
study of these factors may provide clues for potential mechanisms of vaccine efficacy. In 
addition, sieve analysis has delineated a site in the V2 region of Env that was a critical 
site of immune pressure. If the HIV strain the individual was infected with matched this 
site on the vaccine, then vaccine efficacy jumped up to 48%. Thus, future trials could 
include additional Envs or differing V2 sequences to enhance protection. Tomaras and 
Haynes believe that if multiple antibody specificities and anti-viral functions are 
evaluated, and combined with identifying correlates of HIV infection risk, then an 
efficacious vaccine strategy may be determined. Finally, the RV144 vaccine had a 
60.5% efficacy 12 months post-vaccination, which declined to 31.2% at 42 months post-
vaccination. It may be that the antibody response or cellular immune response was of a 
higher level or quality initially and waned over time. Future vaccine strategies should 
attempt to increase their durability with certain adjuvants in an attempt to maintain 
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efficacy320. 
The Step Trial has been called a failure numerous times due to the increased risk 
of HIV acquisition in the vaccine group 221, but post-hoc studies directly resulting from 
the Step Trial, such as the ones presented in this thesis and others, have moved 
scientific knowledge forward. In this sense, future vaccine studies for mucosally 
transmitted pathogens and mucosally targeted vaccine vectors are now better aware of 
the value of examining different anatomical compartments. The unique phenotypic 
combination of the mucosal surface as the site of HIV transmission, the greatest and 
most rapid depletion of CD4+ T cells due to the high availability of activated CCR5+ 
CD4+ T cells for viral replication, and structural disruption of the mucosal architecture, all 
advocate for careful investigation of this site [reviewed in 104]. An effective HIV vaccine 
would likely have to stop viral replication between the small window of mucosal 
transmission and dissemination of HIV infection throughout the body. A vector-based 
vaccine, or any other modality, may need to induce a high frequency of HIV-specific 
immune responses locally in the mucosa, in addition to, or instead of, just systemically. 
Future work will probably have to determine the duration of this window and induce 
highly effective local responses, which also necessitates establishing correlates of 
protection for HIV (with a range of factors including cell functionality, differentiation 
status, migration patterns, proliferative potential, etc.). These responses certainly cannot 
be evaluated solely from the peripheral blood, although researchers are unlikely to have 
access to mucosal samples from all participants in a large-scale human vaccine trial. 
Therefore, the value of developing a dependable NHP model for HIV (and other 
vaccines) is of utmost importance.  
In addition to the rectal mucosa, vaginal and penile mucosal tissues are 
important sites of HIV transmission to investigate in future studies. The unexpected 
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outcome of the Step Trial led to the realization that mucosal sampling and specimen 
analysis could help to explain the lack of efficacy, and also enhancement of HIV 
susceptibility. The foreskin is the principal site of heterosexual HIV-1 infection in men321 
but there is little known about HIV-1-specific immune responses in foreskin. Specifically, 
exploring the effects of vaccination on the induction or phenotype of SIV/HIV-specific 
immune responses in foreskin has not been extensively performed. Like we show in the 
rectal mucosa in this dissertation, CD4+ T cells in foreskin in humans are highly 
activated, potentially contributing to the risk of HIV-1 infection by increased HIV-1 target 
cells322. Other studies have shown that in rhesus macaques, vaccination with AdV26 
vectored SIV vaccines elicited robust and durable SIV-specific CD4+ and CD8+ T cell 
responses of a largely transitional memory or effector memory phenotype at 
gastrointestinal and cervicovaginal mucosal sites323. Further, a recent study by Balandya 
and colleagues demonstrated the induction of SIV-specific cellular immune responses in 
foreskin of AdV26 and AdV35 vector vaccinated macaques, showing that foreskin T cells 
were more activated than peripheral blood T cells324. In sum, though, it still remains 
unclear whether rectal, vaginal, or penile mucosal tissue T cell activation or other 
immune responses at baseline or after AdV vectored vaccination may affect SIV/HIV 
infection, and therefore further research into these areas is certainly warranted.   
As a whole, HIV vaccine studies have, until recently, been restricted to use of 
either a single or related vaccine vectors, such as AdV vectors derived from different 
serotypes, or different poxvirus vectors, or even combinations with DNA vaccines. 
Combining these different platforms in novel varieties may be useful to induce desired 
HIV responses. Research has even moved towards use of replication-competent viral 
vectors (as opposed to the overwhelmingly predominant use of replication-incompetent 
AdV vectors thus far), which would preferably include some features of live-attenuated 
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viral vaccines. These include adequate replicative capacity to generate a mild infection 
to induce pathogen recognition, provide prolonged exposure to antigens, and employ the 
adaptive immune system. For adenovirus, which naturally infects mucosal surfaces, the 
maintenance of its replicative capacity is preferential and well suited for HIV vaccine 
strategies, but also may risk establishing persistence and potential vaccine transmission 
[reviewed in 325].  
I previously mentioned the use of AdV vectors for malaria, hepatitis C and 
tuberculosis vaccines. These diseases can occur at high rates in HIV endemic areas, 
therefore care should be taken so as to not potentially induce increased risk of HIV 
acquisition due to AdV vectored vaccination for another pathogen, especially since there 
is still no definite clarity as to why the Step Trial failed. Recently, the Bill & Melinda 
Gates Foundation provided a large grant for the development of vaccines against 
tuberculosis, HIV, and malaria, to enable the large-scale production of multiple novel 
chimpanzee adenovirus vector constructs. Since AdV vectors of various serotypes have 
been shown to differ with respect to their subtype, seroprevalence, cell-binding 
receptors, tropism, as well as inducing different gene expression profiles and T cell and 
antibody phenotypic functionality, this has provided validation for some researchers to 
continue to evaluate rare serotype AdV vectors. While one cannot rule out this 
possibility, cross-reactive T cell responses, even to rare AdV vectors, may hinder this 
progress. Notably, plans for a large efficacy trial of an AdV35-based tuberculosis vaccine 
candidate – Crucell AdV35/AERAS-402 – have been significantly scaled back due to the 
observation that the approach is less immunogenic than preliminary results had 
indicated. It seems feasible, though, that if tuberculosis, malaria, hepatitis C and other 
potential AdV vectored vaccines are geared towards immunization in children, then risk 
for HIV infection in that age bracket might not be applicable, assuming that this risk 
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would wane over time. In summary, whether AdV vectors might enhance HIV acquisition 
risk in some individuals is not yet completely discerned, and more work is needed to 
understand how AdV vectored immunization for any pathogen affects interactions 
between AdV-specific CD4+ T cells and persistent adenovirus infections at mucosal 
sites of HIV exposure.    
Besides AdV vectors, another very promising vector is cytomegalovirus (CMV), 
which persists indefinitely after infection since it is a member of the herpesvirus family. 
This persistence leads to constant, low-level immune stimulation that results in a mass 
of effector T cells. Picker et al. have pioneered the use of a rhesus CMV (RhCMV) 
vector for use in a multivalent RhCMV-SIV vaccine that covers much of the SIVmac239 
proteome. When tested in CMV-seropositive RMs, pre-existing CMV infection did not 
affect the immunogenicity of the vector; a significant bonus compared to AdV-based 
vectors. Studies are ongoing and expected to continue into human trials due to their 
success thus far, as Picker’s group has shown protection from SIVmac239 infection in 
50% of RMs with early and durable control 128,300. Although going in this direction is 
hopeful, there are a few challenges that remain with use of this CMV vector.  First, 
studies thus far have used RhCMV, which, like all CMV vectors, is species-specific. 
Therefore, human CMV vectors will need to be developed that exhibit comparable 
results. Second, CMV is a pathogen as well, and currently even has vaccine strategies 
geared towards it. While it is generally nonpathogenic in humans, those who are 
pregnant or immunocompromised may still be exhibit a significant risk. Further CMV 
vector advances in humans will likely necessitate genetic modifications, including a 
reduced ability to spread, limited vector tropism, or the option of vector elimination for 
any adverse outcomes (as CMV is persistent). Finally, it will be interesting to definitively 
determine whether SIV control is governed by CD8+ T cell targeting of unconventional 
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epitopes. Why 50% of challenged of challenged macaques did not show evidence of 
viral load reduction is still unclear, and hopefully future studies will elucidate that 
question326.  
Regardless of which vaccine platform will prove to thrive, its design will need to 
improve upon the magnitude and breadth seen from vaccine trial immune responses 
thus far. Most optimally, this vaccine will be able to induce both broadly neutralizing 
antibodies as well as cytotoxic CD8+ T cell responses, while finding a suitable balance 
for CD4+ memory T cell activation levels. The most effective NHP model for HIV would 
mimic the salient features of initial viral infection and dissemination. Although a perfectly 
parallel system is not feasible, one alternative for future SIV challenge experiments is 
evaluating the dose which humans are exposed to during sexual HIV transmission and 
accurately determining that dose for different SIV challenge viruses. In our titration 
study, we began with 1:5000 (4TCID50), which led to two RM infections, and we also had 
one RM infected in our challenge study at 1:10,000 (2TCID50). During the challenge 
study, we escalated the dose ½ a log every 3 weeks until infection, since we did not 
want to potentially miss an activation-induced SIV susceptibility window. Additionally, we 
were not completely certain on what dose would truly elucidate a difference in SIV 
susceptibility, since our titration was the only previous study we could trust with an 
adequate sample size. If, in future challenge studies, a certain dose of SIV challenge 
stock is established to be analogous to the dose of typical sexual HIV exposure, this 
dose can be used consistently instead of dose-escalation. Notably, the macaque 
infected at the lowest dose of 2TCID50 during our challenge study belonged to the SAdV-
7 vaccine group. It would be interesting to see if a difference in activation-induced SIV 
susceptibility would occur in a similarly designed study, but using the same SIV 
challenge dose.  
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